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Revised Guidelines for HIV Counseling, Testing,
and Referral
Summary
These guidelines replace CDC’s 1994 guidelines, HIV Counseling, Testing, and
Referral Standards and Guidelines, and contain recommendations for public- and
private-sector policy makers and service providers of human immunodeficiency
virus (HIV) counseling, testing, and referral (CTR). To develop these guidelines,
CDC used an evidence-based approach advocated by the U.S. Preventive
Services Task Force and public health practice guidelines. The recommendations
are based on evidence from all available scientific sources; where evidence is
lacking, opinion of “best practices” by specialists in the field has been used.
This revision was prompted by scientific and programmatic advances in HIV
CTR, as well as advances in prevention and the treatment and care of HIV-infected
persons. These advances include a) demonstrated efficacy of HIV prevention
counseling models aimed at behavioral risk reduction; b) effective treatments for
HIV infection and opportunistic infections; c) effective treatment regimens for
preventing perinatal transmission; and d) new test technologies.
Although the new guidelines include many aspects of the previous ones (e.g.,
encouragement of confidential and anonymous voluntary HIV testing, need for
informed consent, and provision of HIV prevention counseling that focuses on the
client’s own risk), the new guidelines differ in several respects, including
• giving guidance to all providers of voluntary HIV CTR in the public and
private sectors;
• using an evidence-based approach to provide specific recommendations for
CTR;
• underscoring the importance of early knowledge of HIV status and making
testing more accessible and available;
• acknowledging providers’ need for flexibility in implementing the
guidelines, given their particular client base, setting HIV prevalence level,
and available resources;
• recommending that CTR be targeted efficiently through risk screening and
other strategies; and
• addressing ways to improve the quality and provision of HIV CTR.
INTRODUCTION
Purpose of the Guidelines
These guidelines were developed for policy makers and service providers in the
many settings that offer voluntary human immunodeficiency virus (HIV) counseling,
testing, and referral (CTR) — public and private, urban and rural, and those with high and
low HIV prevalence (Box 1). The guidelines are intended to be used to develop CTR
services and policies in traditional clinical settings (e.g., sexually transmitted disease
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BOX 1. HIV counseling, testing, and referral (CTR) settings
Settings that provide HIV CTR include but are not limited to the following traditional
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• Women’s health clinics
[STD] clinics, private physicians’ offices) and nontraditional settings (e.g., community-
based or outreach settings [homeless shelters, bars]), which can be important places to
provide access to CTR to persons at increased HIV risk. The Public Health Service is
responsible for ensuring the quality of services in publicly funded programs, and many
aspects of these guidelines focus on such programs. The guidelines could also be useful
for CTR in other settings (e.g., for insurance, military, and blood donation purposes).
Recommendations should be tailored to fit the needs of clients, communities, and pro-
grams within local, state, and federal rules and regulations.
Evolution of the Guidelines
These guidelines revise and update several sets of CDC guidelines for HIV CTR. The
first CDC guidelines, published in 1986, highlighted the importance of offering voluntary
testing and counseling and maintaining confidential records (1 ). In 1987, new guidelines
emphasized the need to decrease barriers to counseling and testing, especially disclo-
sure of personal information (2 ). In 1993, an additional report described the model of HIV
prevention counseling currently recommended — an interactive rather than didactic
model focusing on a personalized HIV risk-reduction plan (3 ). In 1994, HIV Counseling,
Testing and Referral Standards and Guidelines focused on standard counseling and test-
ing procedures and reiterated the importance of the HIV prevention counseling model
and the need for confidentiality of counseling (4 ).
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Because of recent advances in HIV treatment and prevention (5–32, Revised Recom-
mendations for HIV Screening of Pregnant Women ), CDC consulted with multiple part-
ners to revise the 1994 guidelines using an evidence-based approach (33,34 ) and to
expand the target audience to all providers of HIV CTR in the United States (33 ). Where
scientific findings were lacking, recommendations were guided by “best practices” from
specialists in the field. These guidelines were developed through the following five-step
approach:
• Address user needs. A survey was conducted of publicly funded sites that offer HIV
CTR to assess user satisfaction with the 1994 CDC guidelines for HIV CTR. Internal
and external content specialists were consulted on key areas to address.
• Review scientific literature. Approximately 5,000 abstracts were screened and
approximately 600 relevant publications were reviewed and synthesized where
appropriate. Approximately 20 previously published CDC guidelines related to HIV
CTR also were summarized.
• Obtain technical opinion. A panel of technical specialists from public and private
sectors; governmental and nongovernmental agencies; and legal, ethics, and
policy fields was convened to review the recommendations.
• Obtain user input. Internal CDC comments, public and private provider
assessments, key consultant interviews, broad external reviews, and public
comments through the Federal Register were obtained.
• Publish electronically and in hard copy. Single copies of this report are available
from CDC’s National Prevention Information Network (NPIN) website at <http://
www.cdcnpin.org> or by calling (800) 458-5231. The guidelines are also available
at the HIV Counseling, Testing, and Referral website at <http://www.cdc.gov/hiv/
ctr>. They will be updated and posted periodically.
Similarities and Differences Between Current and Previous
Guidelines
Aspects of previous CDC HIV guidelines that are unchanged include
• encouraging availability of anonymous as well as confidential HIV testing;
• ensuring that HIV testing is informed, voluntary, and consented;
• emphasizing access to testing and effective provision of test results;
• advocating routine recommendation of HIV CTR in settings (e.g., publicly funded
clinics) serving clients at increased behavioral or clinical risk for HIV infection;
• recommending use of a prevention counseling approach aimed at personal risk
reduction for HIV-infected persons and persons at increased risk for HIV; and
• stressing the need to provide information regarding the HIV test to all who take the
test.
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Differences in the new guidelines include
• giving guidance to all providers of voluntary HIV CTR in the public and private
sectors;
• using an evidence-based approach to provide specific recommendations for CTR;
• underscoring the importance of early knowledge of HIV status and making HIV
testing more accessible and available;
• acknowledging providers’ need for flexibility in implementing the guidelines, given
their particular client base, setting HIV prevalence level, and available resources;
• recommending that CTR be targeted efficiently through risk screening and other
strategies; and
• addressing ways to improve the quality and provision of HIV CTR.
Advances in HIV/AIDS Prevention and Treatment Interventions
During the past 2 decades, HIV infection and severe HIV-related diseases (e.g.,
acquired immunodeficiency syndrome [AIDS]) have become a leading cause of illness
and death in the United States. As of December 31, 2000, a total of 774,467 persons were
reported with AIDS, and 448,060 of these persons had died; the number of persons living
with AIDS (322,865) was the highest ever reported (35 ). Approximately 800,000–900,000
persons in the United States are infected with HIV, and approximately 275,000 of these
persons might not know they are infected (36 ).
Since the last CTR guidelines were published, many advances have been made in
HIV/AIDS prevention and treatment, including development of effective antiretroviral
therapies that have reduced HIV-related illness and death. However, although medical
treatment has improved the quality and length of life for HIV-infected persons, it cannot
cure HIV disease. Furthermore, the successes of new medical therapies might have led
to relaxed attitudes toward safer sex (e.g., increased incidence of unprotected anal sex
by young men who have sex with men) by HIV-infected persons and uninfected persons
at increased risk (36,37 ). Additional advances include improved understanding of HIV
transmission; a wider array of HIV test technologies; effective prevention counseling
approaches; and practical, beneficial referral strategies — all of which could reduce the
impact of the HIV epidemic in the United States.
Early knowledge of HIV infection is now recognized as a critical component in control-
ling the spread of HIV infection (38 ). Cohort studies have demonstrated that many
infected persons decrease behaviors that transmit infection to sex or needle-sharing
partners once they are aware of their positive HIV status (39–46 ). HIV-infected persons
who are unaware of their infection do not reduce risk behaviors (42,47–49 ). Persons
tested for HIV who do not return for test results might even increase their risk for trans-
mitting HIV to partners (50 ). Because medical treatment that lowers HIV viral load might
also reduce risk for transmission to others (51 ), early referral to medical care could
prevent HIV transmission in communities while reducing a person’s risk for HIV-related
illness and death.
The array of HIV test technologies available has expanded, possibly enhancing a
person’s willingness to be tested and learn his or her HIV status. HIV tests can use
specimens collected by less-invasive methods (e.g., oral fluid, urine, and finger-stick
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blood), in addition to serum specimens collected by venipuncture. Rapid HIV testing
allows clients to receive results the same day, which is useful in urgent medical circum-
stances and settings where clients tend not to return for HIV test results (e.g., some STD
clinics). HIV testing can also be conducted using commercially available home sample
collection devices (52 ).
Also during the 1990s, randomized controlled trials demonstrated that, for persons at
increased HIV risk, certain prevention counseling approaches can be effective in reduc-
ing high-risk behaviors and new sexually transmitted infections (5,18–21 ). The counsel-
ing approach used is critical to effectiveness; interactive counseling approaches directed
at a client’s personal risk and the situations in which risk occurs are more effective than
didactic, informational approaches (5 ). Because personalized prevention counseling can
require more provider time and training than traditional counseling approaches, provid-
ing it to everyone receiving HIV testing might not be feasible. This recognition has led to
a new area of health services research — developing strategies that effectively target
CTR services to persons most likely to benefit from them.
The improved health of HIV-infected persons on antiretroviral therapy, along with
new test technologies and effective counseling approaches, has contributed to an im-
proved understanding of the importance of referral to needed services. In addition, new
guidelines for partner counseling and referral services (PCRS) (27 ) and prevention case
management (28 ) were developed specifically for publicly funded clinics and could also
be useful to providers in other settings. Specialists in the field have also identified situa-
tions in which additional counseling or psychosocial support services might benefit HIV
prevention efforts. Finally, advances in several areas have led to new guidelines for
preventing mother-to-child transmission (see Revised Recommendations for HIV Screen-
ing of Pregnant Women ), treating opportunistic infections (23,53 ) and other sexually
transmitted (29 ) and bloodborne diseases (30–32 ), and managing occupational and
nonoccupational exposure and prophylaxis (54,55 ). These developments were consid-
ered in the formulation of the new CTR guidelines.
Despite these advances in HIV prevention and care, a substantial number of opportu-
nities for HIV prevention through CTR are missed. At publicly funded sites, approxi-
mately 70% of persons tested received their results and information regarding the test,
but fewer persons likely received HIV prevention counseling and referrals. In private
settings, a lower proportion of all clients are tested, and few receive prevention counsel-
ing and referrals (56–59 ). In many potential testing settings (e.g., emergency depart-
ments), HIV prevention counseling and testing are not uniformly offered, and data
regarding types, completion, and effectiveness of referrals are not routinely collected.
Goals of HIV CTR
• Ensure that HIV-infected persons and persons at increased risk for HIV
— have access to HIV testing to promote early knowledge of their HIV status;
— receive high-quality* HIV prevention counseling to reduce their risk for
transmitting or acquiring HIV; and
* Delivered according to recommended protocols (for counseling, referral, and evaluation) or
regulatory standards (for testing).
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—  have access to appropriate medical, preventive, and psychosocial support
services.
• Promote early knowledge of HIV status through HIV testing and ensure that all
persons either recommended or receiving HIV testing are provided information
regarding transmission, prevention, and the meaning of HIV test results.
Principles of HIV CTR
Effective HIV CTR is based on the following principles:
• Protect confidentiality of clients who are recommended or receive HIV CTR
services. Information regarding a client’s use of HIV CTR services should remain
private (i.e., confidential). Personal information should not be divulged to others in
ways inconsistent with the client’s original consent.
• Obtain informed consent before HIV testing. HIV testing should be voluntary and
free of coercion. Informed consent before HIV testing is essential. Information
regarding consent may be presented orally or in writing and should use language
the client can understand. Accepting or refusing testing must not have detrimental
consequences to the quality of care offered. Documentation of informed consent
should be in writing, preferably with the client’s signature. State or local laws and
regulations governing HIV testing should be followed.
Information regarding consent may be presented separately from or combined
with other consent procedures for health services (e.g., as part of a package of
tests or care for certain conditions). However, if consent for HIV testing is combined
with consent for other tests or procedures, the inclusion of HIV testing should be
specifically discussed with the client. For a discussion of HIV testing in pregnant
women, consult the guidelines for HIV screening of pregnant women (see Revised
Recommendations for HIV Screening of Pregnant Women ).
• Provide clients the option of anonymous HIV testing. Anonymous testing (i.e.,
consented voluntary testing conducted without a client’s identifying information
being linked to testing or medical records, including the request for testing or test
results) has been used widely and effectively. Anonymous testing can benefit the
health of individual persons and the public by prompting earlier entry into medical
care (60 ). Persons who would otherwise not be tested might seek anonymous HIV
testing and learn their HIV status. Consistent with public health best practices,
states in which anonymous testing is not available should reconsider their policy.
When the client has no clear preference regarding testing type, confidential testing
(i.e., information documented in client’s record) should be recommended to
promote receipt of test results and linkage to follow-up counseling and referral for
needed services. Clients opting for anonymous testing should be informed that the
provider cannot link the client’s test result to the client by name. Therefore, if the
client does not return for test results, the provider will not be able to contact the
client with those results.
• Provide information regarding the HIV test to all who are recommended the test
and to all who receive the test, regardless of whether prevention counseling is
provided. The information should include a description of ways in which HIV is
transmitted, the importance of obtaining test results, and the meaning of HIV test
results.
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• Adhere to local, state, and federal regulations and policies that govern provision
of HIV services. Laws at the local, state, and federal levels might address aspects
of HIV services or regulate how services are provided to particular persons (e.g.,
minors). In addition, policies, local ordinances, funding source requirements, and
planning processes could also affect a provider’s decisions regarding which
services to provide and how to provide them.
• Provide services that are responsive to client and community needs and
priorities. Providers should work to remove barriers to accessing services and
tailor services to individual and community needs. To ensure that clients find
services accessible and acceptable, services can be offered in nontraditional
settings (i.e., community-based or outreach settings); hours of operation can be
expanded or altered; unnecessary delays can be eliminated (e.g., integrating
counseling and testing for STDs/HIV with counseling and testing for hepatitis); test
results can be obtained more easily (e.g., with rapid testing or by telephone in
certain situations); and less-invasive specimen collection can be used (e.g., oral
fluid, urine, or finger-stick blood).
• Provide services that are appropriate to the client’s culture, language, sex, sexual
orientation, age, and developmental level. These factors could affect how the
client seeks, accepts, and understands HIV services. Providers should consider
these factors when designing and providing HIV services to increase the likelihood
of return for test results and acceptance of counseling and referral services.
• Ensure high-quality services. To ensure ongoing, high-quality services that serve
client and community needs, providers should develop and implement written
protocols for CTR and written quality assurance and evaluation procedures. Many
state and local health departments have substantial expertise in providing and
monitoring the quality of HIV CTR services and can be a resource to private
providers or community-based or outreach settings initiating these services.
TARGETED VERSUS ROUTINELY RECOMMENDED HIV CTR
Providers in all settings (traditional and nontraditional) should ideally recommend
CTR to all clients on a routine basis to ensure that all clients who could benefit from CTR
receive these services. However, resources might be insufficient to permit this practice.
Therefore, these guidelines contain recommendations aimed at ensuring that as many
persons as possible who are HIV-infected or at risk for HIV who do not know their HIV
status have access to testing, prevention counseling, and referrals.
Routinely Recommending CTR to All Clients Versus
Targeting CTR to Selected Clients
Studies have documented that, in settings serving clients at increased behavioral and
clinical risk for HIV infection, targeting HIV testing based on reported risk factors will miss
many HIV-infected clients (61–69 ). However, in low prevalence settings, where most
clients have minimal risk, targeting clients for HIV testing based on risk screening might
be more feasible for identifying small numbers of HIV-infected persons (70 ). Providers
should consider three factors in determining whether to recommend HIV CTR to all
clients or to target only selected clients.
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• Type of setting.
• HIV prevalence of the setting.
• Behavioral and clinical HIV risk of the individual clients in the setting.
Although certain types of settings serve populations at increased risk (e.g., STD clin-
ics), others might serve individual clients at increased risk (e.g., private physicians’
offices in areas of low prevalence). Individual risk can be ascertained through risk screen-
ing. Under certain circumstances — perinatal transmission, acute occupational expo-
sure, and acute nonoccupational (i.e., high-risk sexual or needle-sharing) exposure —
providers should recommend HIV CTR regardless of setting prevalence or behavioral or
clinical risk, based on the respective guidelines (Revised Recommendations for HIV
Screening of Pregnant Women,54,55 ).
Using Prevalence Data to Establish Service Priorities
Few data exist to define “high” and “low” HIV prevalence and describe how these
definitions could help develop and prioritize HIV CTR services. A study conducted in the
early 1990s for acute care hospitals with >1% HIV prevalence reported that routine
voluntary HIV testing of all patients within a specific age range could be a feasible way to
identify a large proportion of HIV-infected patients (71 ). This 1% prevalence can be used
as general guidance for whether to routinely recommend or target HIV counseling and
testing in other settings.
The threshold of HIV prevalence that should lead to routine recommendations for HIV
testing of all clients within a setting can vary within and across settings and should be set
in consideration of available resources. Services could be routinely recommended in
settings with HIV prevalence rates <1% but higher than other settings in the community,
according to U.S. prevalence data (72 ). If HIV prevalence data are outdated or unknown,
providers should consult their local or state health department for assistance in deter-
mining appropriate HIV CTR strategies. Alternatively, providers could employ routine
voluntary testing to obtain information on prevalence in their particular settings.
Because of the availability of antiretroviral therapy to reduce the risk for perinatal
HIV transmission, all pregnant women should be recommended HIV testing regardless of
setting prevalence or behavioral or clinical risk (see Revised Recommendations for HIV
Screening of Pregnant Women ).
Determining Individual HIV Risk Through Risk Screening*
A client’s individual HIV risk can be determined through risk screening based on self-
reported behavioral risk (Box 2) and clinical signs or symptoms. Behavioral risks include
injection-drug use or unprotected intercourse with a person at increased risk for HIV.
Clinical signs and symptoms include STDs, which indicate increased risk for HIV infection,
or other signs or symptoms (e.g., of acute retroviral or opportunistic infections), which
might suggest the presence of HIV infection. Insufficient data exist to support the efficacy
of any one risk-screening approach over others (e.g., face-to-face discussion or inter-
views, self-administered questionnaires, computer-assisted interviews, or simple open-
ended questions asked by providers) (Box 2) (61,70 ).
* Risk screening differs from risk assessment, which is a part of HIV prevention counseling
(see HIV Prevention Counseling).
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BOX 2. Examples of two risk-screening strategies to elicit client-reported HIV risks
• Open-ended question by provider,  “What are you doing now or what have you
done in the past that you think may put you at risk for HIV infection?”
• Screening questions* (i.e., a checklist) for use with a self-administered
questionnaire, face-to-face or computer-assisted interview, or other instru-
ment: “Since your last HIV test (if ever), have you
— injected drugs and shared equipment (e.g., needles, syringes, cotton,
water) with others?”
— had unprotected intercourse with someone that you think might be infected
(e.g., a partner who injected drugs, has been diagnosed or treated for a
sexually transmitted disease [STD] or hepatitis, has had multiple or
anonymous sex partners, or has exchanged sex for drugs or money)?”
— had unprotected vaginal or anal intercourse with more than one sex
partner?”
— been diagnosed or treated for an STD, hepatitis, or tuberculosis?”
— had a fever or illness of unknown cause?”
— been told you have an infection related to a ‘weak immune system’?”
* Clients who respond affirmatively to >1 of these questions should be considered at
increased risk for HIV.
Recommendations for Routinely Recommended and Targeted
CTR by Setting and Circumstance
Decisions regarding whether to recommend routine or targeted services are based
on the behavioral and clinical HIV risk of the client population in the setting, the level of
HIV prevalence of the setting, and the behavioral and clinical HIV risk of individual clients
(Box 3). These factors should not be used to determine recommendations for CTR in
circumstances in which treatment potential exists (i.e., perinatal transmission and acute
occupational or nonoccupational exposure).
Settings Serving Populations at Increased Behavioral or Clinical Risk
HIV CTR should be routinely recommended for all clients in settings where the client
population is at increased behavioral or clinical risk for acquiring or transmitting HIV
infection, regardless of setting prevalence (Box 4 and Figure 1). These services should be
provided on-site. In these settings, clients with ongoing risk behaviors should be linked to
additional HIV prevention and support services (e.g., PCRS, drug or alcohol prevention
and treatment), as appropriate. HIV-infected clients should receive ongoing HIV preven-
tion counseling applicable to their personal situation.
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BOX 4. Examples of settings that serve populations at increased behavioral or clinical
risk for HIV infection
• Adolescent or school-based health
clinics with high rates of sexually
transmitted diseases (STD)
• Clinics serving men who have sex
with men
• Correctional facilities, prisons, juve-
nile detention centers
• Drug or alcohol prevention and
treatment programs
• Freestanding HIV test sites
• Homeless shelters
• Outreach programs (e.g., syringe
exchange programs)
• STD clinics
• Tuberculosis (TB) clinics*
* Only persons with confirmed or suspected TB and their contacts should routinely be
recommended HIV CTR.
BOX 3. Clients who should be recommended HIV prevention counseling, testing,
and referral
• All clients in settings serving client populations at increased behavioral or
clinical HIV risk (regardless of setting HIV prevalence).
• Individual clients in settings with <1%* HIV prevalence who†
— have clinical signs or symptoms suggesting HIV infection (e.g., fever or
illness of unknown origin, opportunistic infection [including active
tuberculosis disease] without known reason for immune suppression),
— have diagnoses suggesting increased risk for HIV infection (e.g., another
sexually transmitted disease [STD] or bloodborne infection),
— self-report HIV risks (see Box 2), or
— specifically request an HIV test.
• All clients in settings with a >1%§ HIV prevalence.¶
• Regardless of setting prevalence or behavioral or clinical risk,
— all pregnant women,¶
— all clients with possible acute occupational exposure, and
— all clients with known sexual or needle-sharing exposure to an HIV-infected
person.
* Or lower than other settings in the community.
† Constitutes risk screening; see Determining Individual HIV Risk Through Risk
Screening.
§ Or higher than other settings in the community.
¶ Clients should be routinely recommended testing, and if risk is identified during risk
screening, they should also be recommended HIV prevention counseling and referral.
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FIGURE 1. An example of counseling, testing, and referral in settings serving popula-
tions at increased behavioral or clinical HIV risk
Low Prevalence Settings
In low prevalence settings (e.g., <1%, see Using Prevalence Data to Establish Service
Priorities) where the client population is generally not at increased behavioral or clinical
HIV risk, CTR should be targeted to clients based on risk screening (Figure 2). Prevention
counseling and referral are recommended for persons at increased risk even if HIV
testing is declined. Any client who requests HIV testing should receive it, regardless of
risk. These settings likely represent most health-care settings.
High Prevalence Settings
In high prevalence settings (e.g., >1%), all clients should be routinely recommended
HIV testing (Figure 3). Risk screening should be used to determine if HIV prevention
counseling and referral should also be recommended. CTR should be provided on-site. In
these settings, clients with ongoing risk behaviors identified during risk screening should
be linked to additional HIV prevention and support services (e.g., PCRS and drug or
alcohol prevention and treatment), as appropriate.
Circumstances For Which HIV Preventive Treatment Exists
Prophylaxis exists for a limited number of situations: perinatal transmission, acute
occupational exposure, and acute nonoccupational (i.e., high-risk sexual or needle-
sharing) exposure. Regardless of population risk, setting prevalence, or individual
behavioral or clinical risk, voluntary HIV testing should be routinely recommended to a)
all pregnant women, b) clients with acute occupational exposure, and c) clients with
acute nonoccupational (e.g., high-risk sexual or needle-sharing) exposure. Regardless of
whether a client receives an HIV test, HIV prevention counseling and referral should
HIV prevention counseling and HIV testing
with informed consent and information
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FIGURE 3. An example of HIV counseling, testing, and referral in high prevalence
settings
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target pregnant women based on risk screening and be routinely recommended to cli-
ents with either acute occupational or nonoccupational exposures. For further informa-
tion, consult the respective guidelines on perinatal transmission, acute occupational
exposure, and acute nonoccupational exposure (Revised Recommendations for HIV
Screening of Pregnant Women,54,55 ).
A Framework for Implementing HIV CTR
CTR are interrelated interventions that ideally should be integrated and offered in all
settings. However, these guidelines acknowledge public and private providers’ needs for
flexibility. Certain providers might be able to offer prevention counseling but not an HIV
test, whereas others might be able to offer an HIV test but not prevention counseling.
Although all providers in settings serving populations at increased behavioral or clinical
risk for HIV (e.g., STD clinics) should provide HIV CTR on-site, not all can. These providers
should maintain clear and appropriate methods of referral to providers of prevention
counseling or testing elsewhere. To ensure client referral, providers who offer HIV coun-
seling and testing should collaborate with providers serving populations at increased risk
for HIV who might not provide these services.
HIV COUNSELING
HIV counseling seeks to reduce HIV acquisition and transmission through the
following:
• Information. Clients should receive information regarding HIV transmission and
prevention and the meaning of HIV test results. Provision of information is different
from informed consent.
• HIV prevention counseling. Clients should receive help to identify the specific
behaviors putting them at risk for acquiring or transmitting HIV and commit to steps
to reduce this risk. Prevention counseling can involve >1 sessions.
Information
All clients who are recommended or who request HIV testing should receive the
following information, even if the test is declined:
• Information regarding the HIV test and its benefits and consequences.
• Risks for transmission and how HIV can be prevented.
• The importance of obtaining test results and explicit procedures for doing so.
• The meaning of the test results in explicit, understandable language.*
• Where to obtain further information or, if applicable, HIV prevention counseling.
• Where to obtain other services (see Typical Referral Needs).
* For example, “A negative test means no HIV was found. But if you were exposed to HIV
recently — in the last 1–2 months — this test may not be able to pick that up.” See Negative
HIV Test Results.
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In certain settings where HIV testing is offered, other useful information includes
a) descriptions or demonstrations of how to use condoms correctly; b) information
regarding risk-free and safer sex options (73 ); c) information regarding other sexually
transmitted and bloodborne diseases; d) descriptions regarding the effectiveness of
using clean needles, syringes, cotton, water, and other drug paraphernalia; e) informa-
tion regarding drug treatment; and f) information regarding the possible effect of HIV
vaccines on test results for persons participating in HIV vaccine trials (see Additional
Counseling Considerations for Special Situations and Positive HIV Test Results).
For efficiency, information can be provided in a pamphlet, brochure, or video rather
than a face-to-face encounter with a counselor. This approach allows the provider to
focus face-to-face interactions on prevention counseling approaches proven effective
with persons at increased risk for HIV infection. Information should be provided in a
manner appropriate to the client’s culture, language, sex, sexual orientation, age, and
developmental level. Certain informational videos and large-group presentations that
provide explicit information regarding correct use of condoms have proven effective in
reducing new STDs (19–21,74 ) and could be effective in reducing HIV.
HIV Prevention Counseling
HIV prevention counseling should focus on the client’s own unique circumstances and
risk and should help the client set and reach an explicit behavior-change goal to reduce
the chance of acquiring or transmitting HIV. HIV prevention counseling is usually, but not
always, conducted in the context of HIV testing. The client-centered* HIV prevention
counseling model involves two brief sessions (4,5,75 ), whereas other effective models
are longer or involve more sessions (5–8,10,11,13–18,76–79 ). Regardless of the model
used, in HIV prevention counseling, the counselor or provider focuses on assessing the
client’s personal risk or circumstances and helping the client set and reach a specific,
realistic, risk-reduction goal. These guidelines avoid using the terms “pretest”and
“posttest” counseling to underscore that prevention counseling is a risk-reduction pro-
cess that might involve only one or >1 session.
Several models for HIV prevention counseling in conjunction with HIV testing have
been developed, evaluated in controlled studies, and documented to be efficacious in
changing behavior or reducing sexually transmitted infections, including individual face-
to-face counseling (5,12 ), large- and small-group counseling with a facilitator
(6,16,18,79 ), and video-based counseling (19 ). For more information regarding inter-
ventions, see The Compendium of HIV Prevention Interventions with Evidence of Effec-
tiveness at <http://www.cdc.gov/hiv/pubs/hivcompendium.pdf>.
Client-Centered HIV Prevention Counseling
Since 1993, CDC has recommended one interactive counseling model, called client-
centered HIV prevention counseling (3,4 ), which involves two face-to-face sessions with
a provider or counselor (3–5,75,80 ). This model has traditionally used a two-step HIV
* Client-centered is used here to mean that the counseling sessions focus on the client’s own
risk circumstances, risk behaviors, and prevention needs. This term should not be confused
with the more intensive, client-centered approach advocated by psychologist Carl R. Rogers,
although some skills and strategies that involve the client in the prevention counseling
process might be similar (Rogers CR. Client-centered therapy: its current practice,
implications, and theory. Boston, MA: Houghton Mifflin, 1951).
Vol. 50 / No. RR-19 MMWR 15
testing approach in which clients are physically present at a setting for the HIV test (initial
session) and then return for HIV test results (follow-up session). Each session might
require 15–20 minutes (including testing and referral) for clients at increased risk for HIV,
but could take only a few minutes for those at lower risk. In the first session, a personal-
ized risk assessment* encourages clients to identify, understand, and acknowledge the
behaviors and circumstances that put them at increased risk for acquiring HIV. The ses-
sion explores previous attempts to reduce risk and identifies successes and challenges in
these efforts. This in-depth exploration of risk allows the counselor to help the client
consider ways to reduce personal risk and commit to a single, explicit step to do so. In the
second session, when HIV test results are provided, the counselor discusses the test
results, asks the client to describe the risk-reduction step attempted (and acknowledges
positive steps made), helps the client identify and commit to additional behavioral steps,
and provides appropriate referrals (e.g., to PCRS).
In one large, randomized, controlled trial, this model was reported to be
• effective at reducing high-risk sexual behaviors and new STDs (5 );
• feasible to use even in busy publicly funded clinics;
• acceptable to clients, counselors, and health-care providers (80 ); and
• cost-effective at preventing STDs in persons at increased risk for HIV (81–83 ).
The model was reported to be especially effective among adolescents and persons
with ongoing sexual risk behaviors (e.g., newly diagnosed STDs) (5 ). Although the ben-
efits of client-centered HIV prevention counseling in reducing high-risk drug behaviors
are unknown, studies have indicated that similar counseling approaches that help clients
explore risks and set specific risk-reduction goals reduce risky drug use behaviors
(39–41,84 ).
Observational studies and reviews of programs in various settings have indicated
that many counselors are still unfamiliar with the specific goals of the client-centered HIV
prevention counseling model (75,85 ) (Amy S. DeGroff, M.P.H., written communication,
2000). Because “client-centered” is sometimes misinterpreted as “face-to-face,” pro-
viders in many HIV test sites deliver face-to-face informational messages in response to
a generic checklist risk assessment. This type of counseling provides advice rather than
encouraging client participation or discussion of personal risk; it seldom focuses on per-
sonal goal setting. “Client-centered” can also be misinterpreted to mean that the coun-
selor should avoid directing the session. Although attentive listening and respect for
clients’ concerns are important elements of effective counseling, the primary goal of
client-centered HIV prevention counseling is risk reduction. HIV prevention counseling
usually requires provider training and support and ongoing quality assurance to achieve
optimal benefit. Providers can contact their state health department’s HIV/AIDS program
office for information on local training opportunities. For information on client-centered
counseling with rapid testing, see Addressing Barriers to HIV Prevention Counseling.
* Personal risk assessment is an essential element of HIV prevention counseling in which the
client and counselor work to understand and acknowledge the client’s personal risk for HIV.
Risk assessment is not synonymous with risk screening (see Determining Individual Client
Risk Through Risk Screening and Box 2), which helps determine which clients should be
recommended HIV CTR.
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Elements of HIV Prevention Counseling
Regardless of the HIV prevention counseling model used, some counseling elements
have been used repeatedly in effective interventions and are recognized by many spe-
cialists as critical in counseling success (Technical Expert Panel Review of CDC HIV Coun-
seling, Testing, and Referral Guidelines; February 18–19, 1999; Atlanta, Georgia).
The following elements should be part of all HIV prevention counseling sessions:
• Keep the session focused on HIV risk reduction. Each counseling session should be
tailored to address the personal HIV risk of the client rather than providing a
predetermined set of information. Although counselors must be willing to address
problems that pose barriers to HIV risk reduction (e.g., alcohol use in certain
situations), counselors should not allow the session to be distracted by the client’s
additional problems unrelated to HIV. Certain counseling techniques (e.g., open-
ended questions [Box 5], role-play scenarios, attentive listening, and a
nonjudgmental and supportive approach) can encourage the client to remain
focused on personal HIV risk reduction.
• Include an in-depth, personalized risk assessment. Sometimes called “enhancing
self-perception of risk,” risk assessment allows the counselor and client to identify,
acknowledge, and understand the details and context of the client’s HIV risk
(17,86,87 ). Keeping the assessment personal, instead of global, will help the client
identify concrete, acceptable protective measures to reduce personal HIV risk (Box
6). The risk assessment should explore previous risk-reduction efforts and identify
successes and challenges in those efforts. Factors associated with continued risk
behavior that might be important to explore include using drugs or alcohol before
sexual activity, underestimating personal risk, perceiving that precautionary
changes are not an accepted peer norm, perceiving limited self-efficacy for
successful change efforts, receiving reinforcement for frequent unsafe practices
(e.g., a negative HIV test result after risk behaviors), and perceiving that
vulnerability is associated with “luck” or “fate” (86–89 ).
• Acknowledge and provide support for positive steps already made. Exploring
previous risk-reduction efforts is essential for understanding the strengths and
challenges faced by the client in reducing risk. Support for positive steps already
taken increases the clients’ beliefs that they can successfully take further HIV risk-
reduction steps. For some clients, simply agreeing to an HIV test is an important
step in reducing risk (5,75 ).
• Clarify critical rather than general misconceptions. In most situations, counselors
should focus on reducing the client’s current risk and avoid discussions regarding
HIV transmission modes and the meaning of HIV test results. However, when
clients believe they have minimal HIV risk but describe more substantial risk, the
counselor should discuss the HIV transmission risk associated with specific
behaviors or activities the clients describe and then discuss lower-risk alternatives
(73 ). For example, if clients indicate that they believe oral sex with a risky sex
partner poses little or no HIV risk, the counselor can clarify that, although oral sex
with an infected partner might result in lower HIV transmission risk than anal sex,
oral sex is not a risk-free behavior, particularly when commonly practiced. If clients
indicate that they do not need to be concerned about HIV transmission among
needle-sharing partners if they use clean needles, the counselor can clarify that
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BOX 5. Examples of closed-ended versus open-ended questions
Closed-ended questions, which might
interfere with client-centered human
immunodeficiency virus (HIV) preven-
tion counseling
Have you ever injected drugs?
OR
Have you (for a male client) ever had
sex with a man?
OR
Have you (for a female client) ever had
sex with a bisexual man?
Have you ever had sex when you were
under the influence of alcohol or drugs?
Do you (always) use condoms when you
have sex?
OR
Can you always use condoms when you
have sex?
Can you always use clean works (i.e.,
needles, syringes, cottons, or cookers*)
when you inject?
Open-ended questions, which pro-
mote client-centered HIV prevention
counseling
What are you doing that you think
may be putting you at risk for HIV
infection?
What are the riskiest things that you
are doing?
If your test comes back positive, how
do you think you may have become
infected?
When was the last time you put your-
self at risk for HIV? What was happen-
ing then?
How often do you use drugs or
alcohol?
How do you think drugs or alcohol
influence your HIV risk?
How often do you use condoms when
you have sex?
When/with whom do you have sex
without a condom? When with a con-
dom?
What are you currently doing to pro-
tect yourself from HIV? How is that
working?
What kinds of things do you do to pro-
tect your partner from getting infected
with HIV? (for HIV-infected clients)
Tell me about specific situations when
you have reduced your HIV risk. What
was going on that made that possible?
How risky are your sex/needle-
sharing partners? For example, have
they been recently tested for HIV?
* Cottons are filters used to draw up the drug solution. Cookers include bottle caps,
spoons, or other containers used to dissolve drugs.
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BOX 6. Examples of global versus specific risk-reduction steps for HIV prevention
counseling
Global risk-reduction steps, which are
unlikely to be effective in changing
behavior
Always use condoms.
Have fewer or less risky partners.
Have safer sex.
Stop injecting drugs.
Specific risk-reduction steps, which
are more likely to be effective in
changing behavior
Buy a condom tomorrow and try it on.
Carry a condom next time I go out
(e.g., to the bar/nightclub).
Starting today, put condoms on the
night stand beside the bed.
Starting tonight, require my partner
to use a condom next time, or I will not
have vaginal (anal) sex.
Stop seeing (specific partner) who is
seeing other people.
Break up with (specific partner)
before getting together with someone
new.
Talk honestly with (specific partner)
about my HIV status and ask about
his/her HIV status.
Next time I’m out with friends and may
have sex, avoid getting “high” on
drugs or alcohol.
Only kissing, etc., with (specific part-
ner) until we both have an HIV test.
Tomorrow, ask (specific partner ) if he
or she has had a recent HIV test and
has been tested for other sexually
transmitted diseases.
Obtain clean works (i.e., needles,
syringes, cottons, or cookers*) tomor-
row so I have them before I use next
time.
Contact drug treatment center and
make appointment.
* Cottons are filters used to draw up the drug solution. Cookers include bottle caps,
spoons, or other containers used to dissolve drugs.
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HIV can be transmitted through the cooker, cotton, or water used by several
persons sharing drugs. With newly identified or uninformed HIV-infected clients,
the counselor should discuss HIV transmission risks associated with specific sexual
or drug-use activities, including those in which the client might not be currently
engaged.
• Negotiate a concrete, achievable behavior-change step that will reduce HIV risk.
Although the optimal goal might be to eliminate HIV risk behaviors, small behavior
changes can reduce the probability of acquiring or transmitting HIV. Behavioral
risk-reduction steps should be acceptable to the client and appropriate to the
client’s situation. For clients with several high-risk behaviors, the counselor should
help clients focus on reducing the most critical risk they are willing to commit to
changing. The step does not need to be a personal behavior change. For many
clients, knowledge of a partner’s recent HIV status (and talking with the partner
about getting an HIV test) might be more critical than personal behavior changes.
The step should be relevant to reducing the client’s own HIV risk and should be a
small, explicit, and achievable goal, not a global goal (Box 6). Identifying the
barriers and supports to achieving a step, through interactive discussion, role-play
modeling, recognizing positive social supports, or other methods will enhance the
likelihood of success (90 ). Writing down the goal might be useful. For clients with
ongoing risk behaviors, referral to additional prevention and support services is
encouraged.
• Seek flexibility in the prevention approach and counseling process. Counselors
should avoid a “one-size-fits-all” prevention message (e.g., “always use
condoms”). Behaviors that are safe for one person might be risky for another (91 ).
For example, unprotected vaginal intercourse might be unsafe with anonymous
partners whose HIV status is unknown, but safe for uninfected persons in a
mutually monogamous relationship. The length of counseling sessions will vary
depending on client risk and comfort (e.g., adolescents might require more time
than adults).
• Provide skill-building opportunities. Depending on client needs, the counselor can
demonstrate or ask the client to demonstrate problem-solving strategies such as a)
communicating safer sex commitments to new or continuing sex partners; b) using
male latex condoms properly; c) trying alternative preventive methods (e.g.,
female condoms); d) cleaning drug-injection equipment if clean syringes are
unavailable; or e) communicating safer drug-injection commitments to persons
with whom the client shares drug paraphernalia (86,92–94 ).
• Use explicit language when providing test results. Test results should be provided
at the beginning of the follow-up session. Counselors should never ask the client to
guess the test results. Technical information regarding the test can be provided
through a brochure or other means so the session can focus on personal HIV risk
reduction for clients with negative tests and other considerations for clients with
positive or indeterminate test results (see Additional Counseling Considerations
for Special Situations). In-depth, technical discussions of the “window period (i.e.,
the time from when a person is infected until they develop detectable HIV antibody)
should be avoided because they could confuse the client and diffuse the
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importance of the HIV prevention message. Counselors should clarify that
negative test results do not mean the client has no HIV risk and work with the client
to reconsider ongoing HIV risk behaviors and the benefits of taking steps to reduce
those risks. A client with ongoing risk behaviors should not be given a false sense of
the safety of those behaviors (i.e., avoid statements like “whatever you were doing
seems to be safe” or “continue to do whatever you are doing now”).
These counseling elements are considered necessary for high-quality counseling.
Specialists in the field (Technical Expert Panel Review of CDC HIV Counseling, Testing,
and Referral Guidelines; February 18–19, 1999; Atlanta, Georgia) also suggested adop-
tion of the following:
• Ensure that the client returns to the same counselor. Consistency of the client and
counselor relationship helps the client feel secure, reduces misunderstanding, and
promotes the likelihood of effective risk reduction. Effective counseling models
tended to use the same counselor for all sessions. When follow-up prevention
counseling sessions must be provided by a different counselor, careful record-
keeping is recommended to ensure high-quality counseling. See The Compendium
of HIV Prevention Interventions with Evidence of Effectiveness at <http://
www.cdc.gov/hiv/pubs/hivcompendium.pdf>.
• Use a written protocol to help counselors conduct effective sessions. A structured
protocol outlining session goals can help keep the counselor focused on risk
reduction. The protocol can include examples of open-ended questions (to help a
new counselor avoid closed-ended questions) and a list of explicit risk-reduction
steps (to help a new counselor avoid accepting a client’s suggestion of global risk-
reduction steps) (95 ).
• Ensure ongoing support by supervisors and administrators. Supervisory support
is essential for effective counseling. Training in HIV counseling approaches that
focus on personal risk reduction is recommended for persons supervising
counselors. Staff appraisals should acknowledge that completion of critical
counseling elements has higher priority than completion of paperwork.
• Avoid using counseling sessions for data collection. If required, paperwork should
be completed at the end of the counseling session or by staff members who are not
counseling. Checklist risk assessments driven by data collection forms are
detrimental to effective counseling because they can encourage even skilled
counselors to use closed-ended questions, limit eye contact, and miss critical
verbal and nonverbal cues. The relevance of any routinely collected data should be
periodically assessed.
• Avoid providing unnecessary information. An emphasis on providing information
might prompt counselors to miss critical HIV prevention opportunities and cause
clients to lose interest. Discussion of theoretical HIV risks (e.g., sex with a person
with hemophilia or needle exposures through tattoos) tends to shift the focus away
from the client’s actual HIV risk situations to topics that are more “comfortable” or
easy to discuss but irrelevant to the client’s risk.
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Who Should Deliver Prevention Counseling
In any setting where HIV testing is provided, existing personnel can be effective
counselors if they have the desire and appropriate training and employ the essential
counseling elements (5,80 ). Advanced degrees or extensive experience are not neces-
sary for effective HIV prevention counseling, though training is (80 ). Training in counsel-
ing is available (see Ensuring High-Quality HIV Prevention Counseling). In situations where
primary health-care providers (e.g., physicians) might not be able to provide prevention
counseling, auxiliary health professionals trained in HIV prevention counseling models
can provide this service. Although peer counseling has been successful in certain situa-
tions (18 ), research does not support an explicit risk-reduction need or benefit to match-
ing clients with counselors based on same or similar backgrounds, sex, ethnicity, age, or
peer group for intervention efficacy (96–98 ). The following skills and counselor charac-
teristics were identified by specialists in the field as important for effective HIV preven-
tion counseling (Technical Expert Panel Review of CDC HIV Counseling, Testing, and
Referral Guidelines; February 18–19, 1999; Atlanta, Georgia):
• Completion of standard training courses in client-centered HIV prevention
counseling or other risk-reduction counseling models.
• Belief that counseling can make a difference.
• Genuine interest in the counseling process.
• Active listening skills.
• Ability to use open-ended rather than closed-ended questions (Box 5).
• Ability and comfort with an interactive negotiating style rather than a persuasive
approach.
• Ability to engender a supportive atmosphere and build trust with the client.
• Interest in learning new counseling and skills-building techniques.
• Being informed regarding specific HIV transmission risks (73 ).
• Comfort in discussing specific HIV risk behaviors (i.e., explicit sex or drug
behaviors).
• Ability to remain focused on risk-reduction goals.
• Support for routine, periodic, quality assurance measures.
Additional Counseling Considerations for Special Situations
• Persons with newly identified HIV infection. Clients with newly identified HIV
infection have immediate and long-term needs. Some clients might be better
prepared to receive positive test results than others. The emotional impact of
hearing an HIV-positive test result might prevent clients from clearly
understanding information during the session in which they receive their results.
Providers should provide appropriate referrals (see Typical Referral Needs) and,
when necessary, additional sessions.
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When a client receives the test result, the provider should ensure that the client
understands it. As part of HIV prevention counseling, providers should explicitly
discuss and clarify any misconceptions regarding HIV transmission risk to partners
associated with specific sexual or needle-sharing activities. Clients should be
advised to refrain from donating blood, plasma, or organs. For sexually active
clients who are not in mutually monogamous partnerships, providers should also
address strategies to prevent other sexually transmitted or bloodborne infections
(e.g, gonorrhea, syphilis, chlamydia, herpes simplex virus, human herpes virus
type 8 [the virus linked to Kaposi sarcoma], hepatitis B virus, hepatitis C virus, and
cytomegalovirus).
The first few months after persons learn they are HIV infected are important for
accessing medical and other support services to help them obtain treatment and
establish and maintain behavior changes that reduce the likelihood of transmitting
the virus to others. For example, persons with ongoing risks might be referred for
prevention counseling to prevent transmission to others or for prevention case
management. For all newly identified clients, a follow-up appointment 3–6 months
after diagnosis is recommended by some specialists (99 ) to assess whether clients
were able to initiate medical care, minimize transmission risk to uninfected
partners, and access other needed services (e.g., partner counseling and referral
services). See guidance on partner counseling and referral services (27 ) and
prevention case management (28 ).
• Persons with a single, recent nonoccupational HIV exposure. After a reported
sexual, injection-drug use, or other nonoccupational exposure to HIV (55 ),
providers should refer clients for prompt initiation of evaluation, counseling, and
follow-up services. Early postexposure prophylaxis could reduce the likelihood of
becoming infected with HIV, although the degree to which early treatment can
prevent new infection after acute nonoccupational HIV exposure is unclear.
Further guidance on nonoccupational HIV exposure is available (55 ).
• Persons with indeterminate HIV test results. Until follow-up test results are
available, persons with an indeterminate result should receive information
regarding the meaning of test results. HIV prevention counseling should be the
same as for a person with newly identified HIV infection. Behaviors that minimize
the risk for HIV transmission to sex and needle-sharing partners should be
emphasized, even if the client reports no risk behaviors. Clients with repeated
indeterminate test results >1 month apart are unlikely to be HIV-infected and can
be provided test results in the same way as clients with negative test results,
unless recent HIV exposure is suspected (see Indeterminate Test Results).
• Persons seeking repeat HIV testing. In addition to brief prevention counseling
sessions, ongoing HIV prevention counseling aimed at personal risk reduction
might be useful for persons seeking repeated HIV testing who have continued HIV
risk. Counselors should encourage clients to explore alternative prevention
strategies and to identify and commit to additional risk-reduction steps. Clients with
ongoing risk behaviors might benefit from referral to other HIV prevention and
support services because their current risk behavior might be reinforced by
repeated negative HIV test results or they might view HIV testing as protective
(100 ). More information on prevention case management is available (28 ) (see
Ongoing Exposure).
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• Persons who use drugs. Persons who inject drugs  might also be at increased risk
for acquiring HIV through unprotected sex with an HIV-infected partner (101–103 ).
For injection-drug users (IDUs), intervention studies indicate that personalized,
interactive prevention counseling models using goal-setting strategies might be
effective in reducing injection-drug and sexual-risk behaviors (39–41,84 ).
Evidence also supports the efficacy of community strategies (e.g., methadone
maintenance programs or other drug treatment programs, outreach programs,
and syringe exchange) to reduce new HIV infections among IDUs (104–108 ).
Specialists in the field advocate recommending such strategies, along with
individual HIV prevention counseling, to persons who inject drugs.
• Sex or needle-sharing partners of HIV-infected persons. Sex or needle-sharing
partners of HIV-infected persons should be encouraged to have HIV prevention
counseling and testing. Partners who are HIV discordant (i.e., one person is HIV-
infected and the other is uninfected) should receive counseling aimed at
preventing HIV transmission from the infected to the uninfected partner, including
explicit discussion and clarification of any misconceptions regarding HIV
transmission risk associated with specific sexual or needle-sharing activities. In
addition, many HIV-discordant couples benefit from ongoing HIV prevention
counseling aimed at personal risk reduction or from couples counseling that
teaches safe sexual practices and proper condom use (27,109–111 ). Little
evidence exists to conclusively support or refute whether simultaneous infection
with >2 subtypes of HIV is likely to occur or, if it does, whether it is associated with
more aggressive or resistant disease (112 ). Researchers are divided on the value
of recommending consistent condom use to prevent HIV sequelae for mutually
monogamous, HIV-infected partners.
• Health-care workers after an occupational exposure. After an occupational
exposure, health-care workers should use measures to prevent transmission
during the follow-up period (54 ). HIV-exposed health-care workers should be
advised that, although HIV is infrequently transmitted through an occupational
exposure, they should abstain from sex or use condoms and avoid pregnancy until
they receive a negative follow-up test result. In addition, they should not donate
blood, plasma, organs, tissue, or semen; if a woman is breast-feeding, she should
consider discontinuing (54 ). Health-care workers should also be advised of the
rationale for postexposure prophylaxis, the risk for occupationally acquired HIV
infection from the exposure, the limitations of current knowledge of the efficacy of
antiretroviral therapy when used as postexposure prophylaxis, the toxicity of the
drugs involved, and the need for postexposure follow-up (including HIV testing),
regardless of whether antiretroviral therapy is taken. Further guidance on
occupational HIV exposure is available (54 ).
• Participants in HIV vaccine trials. HIV-vaccine–induced antibodies may be
detected by current HIV tests and may cause a false-positive result. Trial
participants should be advised that HIV CTR is best provided at the vaccine trial
sites, the vaccine is of unknown efficacy, and HIV risk behavior can result in their
becoming HIV-infected (see Positive Test Results).
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Addressing Barriers to HIV Prevention Counseling
Several factors can prevent provision of high-quality HIV prevention counseling,
including unavailability of trained prevention counselors at the setting in which the HIV
test was conducted, client reluctance, and low rates of client return for test results.
Recommended strategies for addressing these common barriers include a) providing
counseling on-site, b) enhancing client acceptance of counseling by examining and
improving the counseling provided, and c) considering alternate counseling methods.
Provide On-Site Counseling
Cost, lack, or turnover of trained staff members and space constraints are barriers to
providing HIV prevention counseling (113 ). However, given the proven efficacy of pre-
vention counseling models, in settings where HIV prevalence is high or the population
served is at increased risk, the ability to provide such counseling on-site is a high priority,
and efforts should be made to address and remove barriers to providing HIV prevention
counseling on-site. Health educators or other auxiliary staff members trained to discuss
preventive activities such as healthy eating, prenatal education, or smoking cessation
could, if adequately trained, be effective HIV prevention counselors. In the interim, alter-
native resources should be identified, and clearly defined referrals should be made to
settings that can provide high-quality prevention counseling for clients at
increased HIV risk. Systems to ensure that referrals are completed should be established
(see HIV Referral).
Enhance Client Acceptance of HIV Prevention Counseling
Clients who agree to HIV testing but decline HIV prevention counseling often report
they lack time or already are aware of HIV transmission modes. However, experienced
counselors report that clients mainly refuse counseling because they do not perceive the
service to be personally beneficial (Technical Expert Panel Review of CDC HIV Counsel-
ing, Testing, and Referral Guidelines; February 18–19, 1999; Atlanta, Georgia). These
counselors believe that most of these clients are concerned about a specific risk, which
they would be willing to explore if the counseling seemed useful. Three of the most
commonly reported barriers to the perceived usefulness of counseling are the type of
counseling provided, how it is recommended, and the setting of the counseling. In set-
tings where many clients are declining counseling, these barriers and others should be
examined. The counseling might be providing information only rather than addressing
personal risks. Counselors might not be offering counseling in ways appropriate to the
client’s culture, language, sex, sexual orientation, age, or developmental level. The set-
ting might inhibit open discussion of risk (e.g., some outreach settings are not private).
Counseling skills (e.g., attentive listening, use of open-ended questions) that allow clients
to participate might have been overlooked. Even when clients at increased risk refuse
counseling, use of 1–2 open-ended questions that urge clients to examine their personal
situations could prompt personal exploration of risk (e.g, “What were your concerns that
led you to decide to get tested today?”).
Consider Alternative Methods for HIV Prevention Counseling
HIV prevention counseling models proven effective have all used face-to-face (indi-
vidual or group) encounters between counselor and client and involved >2 brief sessions.
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Thus, face-to-face prevention counseling is preferred for clients at increased HIV risk.
Most HIV test sites use an enzyme immunoassay (EIA) and confirmatory test algorithm
that requires several days for final results. The return visit for test result offers an oppor-
tunity to continue prevention counseling in a second, face-to-face meeting. However, in
some settings (e.g., STD clinics, managed care organizations, and other private settings),
many clients do not return for their results (50,114–116 ). In such settings, providers can
adopt strategies that increase clients’ receipt of test results, and counseling strategies
might need to be adapted (117 ).
Telephone Counseling. Limited studies among STD clinic clients at lower risk indi-
cated that substantially more clients learned their HIV infection status when negative
test results were provided by telephone rather than in person (12,117,118 ). Although
home sample collection provides a precedent for providing counseling by telephone to
persons with either negative or positive HIV test results, the efficacy of telephone coun-
seling in reducing HIV risk behaviors or the number of new HIV infections has not been
studied. One study indicated that telephone notification of positive results was associ-
ated with delay in linkage to care (119 ). However, not learning positive test results at all
guarantees a delay in linkage to care. Many specialists recommend that provision of HIV
test results and prevention counseling by telephone be limited to clients whose results
are negative (Technical Expert Panel Review of CDC HIV Counseling, Testing, and Refer-
ral Guidelines; February 18–19, 1999; Atlanta, Georgia). Also, given the known risk-
reduction benefits of face-to-face counseling, lack of efficacy data on telephone
counseling, and concerns regarding disinhibition (e.g., “since my test result is negative,
whatever risks I am taking now may be okay”), telephone counseling should be limited to
clients without known ongoing HIV risk behaviors (e.g., unprotected sex or needle-
sharing with an HIV-infected [or status unknown] partner).
Single-Session Prevention Counseling with Rapid Testing. Rapid tests allow clients to
receive their HIV test results the same day. This process could reduce the number of
clients receiving two prevention counseling sessions. Studies of the efficacy of single HIV
prevention counseling sessions for use with a rapid test are under way. Although some
single-session counseling protocols have been successfully implemented in busy clinics
and are well-accepted by most clients, how well a single counseling session reduces risk
behaviors or the number of new HIV infections is unknown. A counseling protocol for use
with a rapid test is being studied; information is available at <http://www.cdc.gov/hiv/
projects/respect-2>. For clients with identified risk behaviors, referral or rescheduling for
ongoing counseling should be considered.
Ensuring High-Quality HIV Prevention Counseling
All CTR providers should conduct routine, periodic assessments for quality assurance
to ensure that the counseling being provided includes the recommended, essential coun-
seling elements.
Supervisors must be aware of HIV prevention counseling goals and necessary coun-
selor skills. Supervisor and administrator support of HIV counseling models that focus on
personal risk reduction (distinct from provision of information) is critical to effective
counseling. Quality assurance for counseling should contain the following elements:
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• Training and continuing education. Basic training in the use of >1 of the interactive
HIV prevention counseling models aimed at personal risk reduction is
recommended for counselors and supervisors. Counselors should know the
communities they serve and the available referral opportunities. They also might
benefit from formal training on a) transmission and prevention of HIV and other
sexually transmitted and bloodborne diseases, b) the natural history of HIV,
c) recognition and treatment of opportunistic infections, d) new therapeutic agents
used to treat HIV and AIDS, e) PCRS, f) prevention case management, and g) other
HIV prevention and support services available in the community (e.g., services
related to substance abuse assessment, cultural competence, adolescent
concerns, domestic abuse, and health concerns for gay or lesbian clients).
Additional training in specific counseling skills is also warranted (e.g., training on
how to facilitate groups for counselors conducting group sessions). For training
opportunities, providers or supervisors can contact their state health department’s
HIV/AIDS program office.
• Supervisor observation and immediate feedback to counselors. Direct
observation of counseling sessions can help ensure that objectives are being met
(80 ). Supervisors can perform this task periodically (with client consent). Sessions
might also be audiotaped (with client consent), or counseling can be demonstrated
through role-play scenarios between the counselor and supervisor. Observation
and feedback should be structured, and the outcome should be constructive, not
punitive. Supervisors should support positive elements of the prevention
counseling session and provide specific, constructive comments regarding content
areas needing improvement. Observation and feedback should be conducted
regularly for routine counseling. Staff discomfort with observation typically wanes
over time; many counselors report that the sessions are useful in enhancing skills.
When observation is offered routinely, clients seldom refuse to participate. A
suggested time frame for routine, direct observation of an HIV prevention
counselor by the supervisor is twice monthly for the first 6 months, monthly for the
second 6 months, and quarterly for counselors with >1 year of experience. After
observation, supervisors should provide feedback to counselors quickly,
preferably the same week. Observation and feedback forms used in research
studies of client-centered HIV prevention counseling are available at <http://
www.cdc.gov/hiv/projects/RESPECT/default.htm>.
• Periodic evaluation of physical space, client flow, and time concerns. Counseling
sessions should be conducted in a private space where discussion cannot be
overheard. Clients should not wait for long periods between testing and
counseling, and information could be provided during waiting times (e.g., through
videos). Periodic time-flow analyses or client surveys can be used to evaluate
adequacy of space, client flow, and length of waiting period.
• Periodic counselor or client satisfaction evaluations. Evaluations of client
satisfaction can ensure that counseling meets client needs. These evaluations also
can provide important feedback to counselors who otherwise might not see the
benefits of what they do. Evaluations can be brief. Surveys should address
whether specific counseling goals were met, the type of interaction (e.g.,“who
talked more, the counselor or the client?”), and, when applicable, specifics of
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development of the risk-reduction plan (e.g, “what was the behavior change step
that you agreed to work on?”). Linking client and counselor descriptions of a
particular session might be useful. Conducting such evaluations only occasionally
(e.g., for 1–2 weeks once or twice a year) decreases the programmatic burden and
is probably sufficient to identify problems. For more information, see Quality
Assurance and Evaluation of HIV CTR Services.
• Case conferences. Regularly scheduled meetings of counselors allow supervisors
to understand counselors’ skills and areas that need improvement and can help
counselors learn techniques from their colleagues. Case conferences are an
opportunity for counselors to discuss specific or problematic questions asked by
clients, allowing providers to better understand the concerns facing clients who are
HIV-infected or at increased risk for HIV. Case conferences can help offset
counselor fatigue and “burn out” by providing a positive outlet for dealing with
difficult situations. Discussion might focus on a hard-to-address client or specific
elements (e.g., developing acceptable and practical risk-reduction plans with
clients who deny the magnitude of their HIV risk). Frequency of case conferences
should be balanced with client volume, with efforts made to meet at least monthly.
HIV TESTING
Characteristics and Applications of HIV Test Technologies
Only FDA-approved HIV tests should be used for diagnostic purposes. Routine screen-
ing in the United States for HIV-2 and HIV-1 group O infections is not generally recom-
mended unless geographic, behavioral, or clinical information indicates that infection
with these strains might be present. Several HIV test technologies have been approved
by FDA for diagnostic use in the United States. These tests enable testing of different
fluids (i.e., whole blood, serum, plasma, oral fluid, and urine) (Table). The available tech-
nologies
• enable specimen collection procedures that are less invasive and more acceptable
than venipuncture, thus helping expand HIV testing into nontraditional settings
(with home sample collection tests, oral fluid tests, and urine-based tests) (25 );
• enable provision of HIV test results during a single visit at the time of testing (with
rapid tests) (120 ); and
• increase the convenience of HIV testing (with home sample collection tests) (52 ).
The decision to adopt a particular test technology in a clinical or nontraditional setting
should be based on several factors, including
• accuracy of the test,
• client preferences and acceptability,
• likelihood of client returning for results,
• cost and mechanism for provider reimbursement,



















TABLE. Performance attributes and potential applications of HIV test technologies approved by the U.S. Food and Drug
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TABLE. (Continued ) Performance attributes and potential applications of HIV test technologies approved by the U.S. Food and Drug
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* Complexity of specimen collection and testing as categorized by the Clinical Laboratory Improvement Amendments (CLIA). (Schochetman G, George JR, eds. AIDS testing: a comprehensive
guide to technical, medical, social, legal, and management issues. 2 ed. New York, NY: Springer-Verlag, 1994.)
†  All licensed enzyme immunoassays (EIAs) detect HIV-1, but not all detect HIV-2. EIAs that can detect HIV-1 and HIV-2 are required for blood donor screening and are recommended for diagnostic
screening only where HIV-2 infection is likely. No licensed confirmatory test exists for HIV-2. Although current tests detect most HIV-1 group O infections, few detect all such infections.
§  The one rapid test licensed by FDA, Abbott Murex Single Use Diagnostic System (SUDS) HIV-1 test (Abbott Laboratories, Inc., Abbott Park, Illinois) is classified as a moderate-complexity test
and requires on-site laboratory testing capability. Future rapid tests could be classified by CLIA as “waived” and not require on-site laboratory testing capability, depending on the expertise
required to perform the test correctly.
¶  Future rapid tests might be able to be confirmed with a second rapid test to provide an immediate test result with high sensitivity, specificity, and predictive value comparable with EIA/Western
blot (Stetler HC, Granade TC, Nunez CA, et al. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras. AIDS 1997;11:369–75).
** Information on providing “preliminary” positive test results from a single rapid test is available elsewhere (CDC. Update: HIV counseling and testing using rapid tests—United States, 1995.
MMWR 1998;47:211–5).
††  Home sample collection is different from home-use testing. FDA has approved home sample collection, but not home-use HIV test kits (Kassler WJ. Advances in HIV testing technology and
their potential impact on prevention. AIDS Educ Prev 1997;9[suppl B]:27–40).
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• complexity of laboratory services required for the test,
• availability of trained personnel, and
• FDA approval of the test.
Home Testing Versus Home Sample Collection
FDA has not approved home-use HIV test kits, which allow consumers to purchase a
test kit, collect a sample in private, and interpret their own HIV test results in a few
minutes. The Federal Trade Commission has warned that some home-use HIV test kits,
many of which are available on the Internet and in the “gray” market (i.e., unauthorized
imports), supply inaccurate results (121 ). These tests are different from FDA-approved
home sample collection kits (52 ), which allow consumers to purchase test kits, collect a
sample in private, send the sample to a laboratory for testing, and telephone for their HIV
test result, counseling, and referral.
HIV-2 and HIV-1 Group O Infections
Although most HIV infections in the United States are of HIV-1 group B subtype,
current EIAs can accurately identify infections with nearly all non-B subtypes and many
infections with group O HIV subtypes (122 ). Infections with HIV-2 and HIV-1 group O are
rare in the United States (123,124 ), and routine screening for these subtypes is not
generally recommended as part of diagnostic testing except in areas where several such
infections have been identified. Routine screening for HIV-2 might be appropriate in
certain populations where potential risk for HIV-2 infection is higher (e.g., in areas where
West African immigrants have settled) (125 ). Since June 1992, FDA has recommended
routine screening for antibody to HIV-2 (in addition to HIV-1) for all blood and plasma
donations (125 ). Clients with clinical, epidemiologic, or laboratory history that suggests
HIV infection and negative or indeterminate HIV-1 screening tests should receive further
diagnostic testing to rule out HIV infection, potentially including testing for HIV-1 non-B
subtypes (122 ) and HIV-2 (125 ).
Other Test Uses
Viral load and HIV-1 p24 antigen assays are not intended for routine diagnosis but
could be used in clinical management of HIV-infected persons in conjunction with clinical
signs and symptoms and other laboratory markers of disease progression. Although
HIV-1 p24 antigen assays are used for routine screening in blood and plasma centers,
routine use for diagnosing HIV infection has been discouraged because the estimated
average time from detection of p24 antigen to detection of HIV antibody by standard EIA
is 6 days, and not all recently infected persons have detectable levels of p24 antigen
(126 ).
Interpreting HIV Test Results
Standard Testing Algorithm
HIV-1 testing consists of initial screening with an EIA to detect antibodies to HIV-1.
Specimens with a nonreactive result from the initial EIA are considered HIV-negative
unless new exposure to an infected partner or partner of unknown HIV status has
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occurred. Specimens with a reactive EIA result are retested in duplicate. If the result of
either duplicate test is reactive, the specimen is reported as repeatedly reactive and
undergoes confirmatory testing with a more specific supplemental test (e.g., Western
blot or, less commonly, an immunofluorescence assay [IFA]). Only specimens that are
repeatedly reactive by EIA and positive by IFA or reactive by Western blot are consid-
ered HIV-positive and indicative of HIV infection. Specimens that are repeatedly EIA-
reactive occasionally provide an indeterminate Western blot result, which might
represent either an incomplete antibody response to HIV in specimens from infected
persons or nonspecific reactions in specimens from uninfected persons (127 ). Although
IFA can be used to resolve an indeterminate Western blot sample, this assay is not widely
used. Generally, a second specimen should be collected >1 month later and retested for
persons with indeterminate Western blot results. Although much less commonly avail-
able, nucleic acid testing (e.g., viral RNA or proviral DNA amplification method) could
also help resolve an initial indeterminate Western blot in certain situations. A small
number of tested specimens might provide inconclusive results because of insufficient
quantity of specimen for the screening or confirmatory tests. In these situations, a sec-
ond specimen should be collected and tested for HIV infection.
Modified Testing Algorithms
FDA has licensed only one rapid test, but modified testing algorithms are anticipated
when additional rapid HIV tests are approved. If >2 sensitive and specific rapid HIV tests
became available, one positive rapid test could be confirmed with a different rapid test.
This combination has provided positive predictive value compared with the EIA/Western
blot or IFA algorithm (128 ). However, no such algorithms have been adequately
assessed or approved for diagnostic use in the United States.
Positive HIV Test Results
An HIV test should be considered positive only after screening and confirmatory tests
are reactive. A confirmed positive test result indicates that a person has been infected
with HIV. False-positive results when both screening and confirmatory tests are reactive
are rare. However, the possibility of a mislabeled sample or laboratory error must be
considered, especially for a client with no identifiable risk for HIV infection. HIV-vaccine–
induced antibodies may be detected by current tests and may cause a false-positive
result. Persons whose test results are HIV-positive and who are identified as vaccine trial
participants should be encouraged to contact or return to their trial site or an associated
trial site for HIV CTR services.
Negative HIV Test Results
Because a negative test result likely indicates absence of HIV infection (i.e., high
negative predictive value), a negative test need not be repeated in clients with no new
exposure in settings with low HIV prevalence. For clients with a recent history of known
or possible exposure to HIV who are tested before they could develop detectable anti-
bodies (129,130 ), the possibility of HIV infection cannot be excluded without follow-up
testing (29 ). A false negative result also should be considered in persons with a negative
HIV-1 test who have clinical symptoms suggesting HIV-1 infection or AIDS. Additional
testing for HIV-2 and HIV-1 group O infection might be appropriate for these persons.
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Indeterminate HIV Test Results
Most persons with an initial indeterminate Western blot result who are infected with
HIV-1 will develop detectable HIV antibody within 1 month (127,131,132 ). Thus, clients
with an initial indeterminate Western blot result should be retested for HIV-1 infection >1
month later.* Persons with continued indeterminate Western blot results after 1 month
are unlikely to be HIV-infected and should be counseled as though they are not infected
unless recent HIV exposure is suspected.
Nucleic acid tests for HIV DNA or RNA exist, but are not approved by FDA for diagnos-
tic purposes and are not generally recommended for resolving indeterminate Western
blot results. However, in consultation with clinical and laboratory specialists, nucleic acid
testing (if available) might also be useful for determining infection status among persons
with an initial indeterminate Western blot result.
Informing Clients of Test Results
Because low rates of return for test results occur in many settings offering HIV CTR
(133 ), providers should work to ensure that clients tested for HIV infection receive their
test results, particularly HIV-infected clients who might benefit from earlier entry into
care and initiation of antiretroviral therapy. Reducing barriers to testing can maximize
the number and proportion of persons tested for HIV who receive their test results in a
timely manner (see Addressing Barriers to HIV Testing). Adoption of new HIV test tech-
nologies and alternative methods of providing HIV-negative test results should be con-
sidered when face-to-face rates of return for test results are low. Strict confidentiality of
the receipt of the HIV test and the HIV test result must be maintained, regardless of the
method used. Providers unable to locate clients who do not return for test results should
seek support from their local or state health department.
Because knowledge of HIV status is a critical HIV prevention strategy and essential
for entry into care, providers should stress to clients the importance of returning to
receive their test results and establish a plan for doing so with the client. Reminder
systems might be useful. Using alternate HIV test technologies might increase the per-
centage of tested persons who learn their HIV status.
Providing Test Results by Telephone
Many clinicians routinely notify clients of negative test results for various diseases
and conditions by means other than face-to-face (e.g., by telephone). They also ask
clients to return to discuss positive test results that might indicate potential life-
threatening illnesses. This strategy can also be applied, under limited circumstances, to
notifying clients of their HIV test results. Face-to-face provision of HIV test results is
strongly encouraged for HIV-infected clients and HIV-uninfected clients at increased risk
who might benefit from HIV prevention counseling and referral to medical, preventive,
and support services. Providing uninfected clients who are not at increased risk the
option of receiving HIV test results and counseling by telephone — with the understand-
ing that provider assurance of client confidentiality is of paramount importance — might
be appropriate. Limited research indicates that offering clients the option of contacting
* Studies on repeat testing for persons with indeterminate Western blot results have not
included pregnant women (see Revised Recommendations for HIV Screening of Pregnant
Women ).
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the provider by telephone to receive negative HIV results might increase rates of receipt
of results, satisfy client preferences for options, and preserve setting resources without
apparent adverse consequences (52,117,118 ). Although no published research exists
regarding use of telephones for providing positive HIV test results with most HIV test
technologies, limited experience exists on using this method to provide HIV-positive test
results for home sample collection testing (52 ).
Providing Test Results During the Initial Visit Through Rapid Tests
More clients receive their HIV test results with rapid tests because results can be
provided at the testing visit (120 ). Rapid test technology could be useful in urgent medi-
cal circumstances (e.g., when decisions must be made regarding postexposure prophy-
laxis) and in nontraditional settings with low return rates (e.g., community-based or
outreach settings).
During the initial visit, the provider can definitively tell clients who have had a single
rapid HIV test with negative results that they are not infected (120 ), except when retest-
ing might be indicated because of recent known or possible exposure to HIV. A reactive
rapid HIV test result should be considered preliminary until the completion of confirma-
tory testing, and results should be carefully communicated to the client because of the
possibility of a false-positive result.
The likelihood that a positive screening test truly indicates the presence of HIV infec-
tion decreases as HIV prevalence in the tested population becomes lower. Therefore,
false-positive HIV test results are more likely in settings where the tested population
prevalence is lower than in settings where the tested population prevalence is higher.
When a preliminary, positive rapid test is explained to clients, phrases like “a good
chance of being infected” or “very likely infected” can be used to indicate the likelihood
of HIV infection and qualified based on the HIV prevalence in the setting and the client’s
individual risk (120 ). Further testing is always required to confirm a reactive screening
test result.
Follow-up Testing in Clients with Negative HIV Test Results
A negative HIV test usually indicates the absence of HIV infection (29 ). Because
recent infection cannot be excluded without follow-up testing (see Negative HIV Test
Results), the appropriate timing and frequency for follow-up testing among clients with
negative HIV test results has not been firmly established. Providers should consider the
following factors related to individual client needs when recommending the timing and
frequency for follow-up HIV testing:
• Timing of the last potential exposure.
• Probability of HIV infection given type of exposure.
• Presence or likelihood of ongoing risk behavior.
• Likelihood of returning for follow-up HIV testing, prevention counseling, and
referral.
• Client anxiety.
• Provider and client relationship.
• Resource constraints.
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Recent Exposure
Follow-up testing might be appropriate for clients who have negative test results but
who have not had time to develop detectable antibody after a recent documented occu-
pational (54 ) or nonoccupational (sexual or needle-sharing) (55 ) exposure to HIV-
infected persons or persons at increased risk for HIV with unknown HIV status. The timing
of follow-up testing should provide assurance that the exposure did not lead to infection.
Follow-up testing should be conducted in a timely manner so clients identified as HIV-
infected can receive appropriate antiretroviral treatment and prevention and support
services as soon as possible.
Single Possible or Known Exposure
Most infected persons will develop detectable HIV antibody within 3 months of expo-
sure (126 ). If the initial negative HIV test was conducted within the first 3 months after
exposure, repeat testing should be considered >3 months after the exposure occurred to
account for the possibility of a false-negative result. If the follow-up test is nonreactive,
the client is likely not HIV-infected. However, if the client was exposed to a known HIV-
infected person or if provider or client concern remains, a second repeat test might be
considered >6 months from the exposure. Rare cases of seroconversion 6–12 months
after known exposure have been reported (134 ). Extended follow-up testing beyond 6
months after exposure to account for possible delayed seroconversion is not generally
recommended and should be based on clinical judgment and individual clients
needs (54 ).
Ongoing Exposure
Persons with continued HIV risk behavior pose a special challenge for follow-up test-
ing. In some settings, clients with ongoing risk represent a substantial proportion of those
receiving HIV CTR. In most circumstances, follow-up HIV testing should be recommended
periodically for clients with ongoing risk behavior. Follow-up testing would monitor the
client’s HIV status, but also promote continued client contact, opportunities for HIV pre-
vention counseling (see Additional Counseling Considerations for Special Situations),
and referral to additional preventive and support services.
No Identifiable Risk
In general, persons with no recent identifiable risk for HIV infection should receive
additional HIV prevention counseling and follow-up testing when requested. Efforts should
be made to understand why these clients repeatedly seek follow-up testing. These cli-
ents should be considered for in-depth prevention counseling and referral to support
services, where appropriate.
Special Considerations
 General recommendations for follow-up testing might not be applicable in all circum-
stances. In certain circumstances (e.g., when persons are simultaneously exposed to
hepatitis C virus and HIV [54 ] and when persons have received HIV vaccines), guidance
should be provided only after consultation with specialists.
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Addressing Barriers to HIV Testing
Knowledge of HIV infection status can benefit the health of individual persons and the
community. Thus, HIV testing should be as convenient as possible to promote client
knowledge of HIV infection status. Efforts should be made to remove or lower barriers to
HIV testing by ensuring that
• testing is accessible, available, and responsive to client and community needs and
priorities;
• anonymous and confidential HIV testing are available;
• the testing process considers the client’s culture, language, sex, sexual orientation,
age, and developmental level; and
• confidentiality is maintained (see Principles of HIV Counseling, Testing, and
Referral).
Acceptance of HIV testing is reportedly lower when clients have been tested previ-
ously and are fearful of their ability to cope with their test results (112,113 ). Testing is
more likely to be accepted when
• clients perceive their own HIV risk and acknowledge behaviors placing them at
increased risk (135 );
• testing is voluntary and routinely offered to clients rather than clients having to
request it (113,136 );
• protections for client confidentiality are in place (113,137 );
• anonymous testing is available (113,138 );
• alternate HIV test technologies are offered to clients (26 );
• providers recommend testing as part of appropriate medical care (139,140 ); and
• providers (141 ) and clients (113 ) perceive HIV counseling and testing to be
beneficial for early diagnosis and prevention purposes.
Ensuring High-Quality Testing
Testing activities should be coordinated with state and local laboratories to ensure
high-quality HIV testing through proper specimen collection, storage, and transport. Labo-
ratory errors most often occur in the preanalytic (i.e., specimen collection, labeling, trans-
porting, processing, and storing) and postanalytic steps of testing (i.e., results validation
and reporting) (142–144 ) rather than during the test itself. Laboratories performing HIV
testing must be enrolled in proficiency testing programs and conduct activities in accor-
dance with regulatory standards outlined by the Clinical Laboratory Improvement
Amendments (CLIA) of 1988 (145 ). Many states have additional licensing requirements
for laboratories conducting diagnostic HIV testing.
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HIV REFERRAL
Definition of Referral
In the context of HIV prevention counseling and testing, referral is the process by
which immediate client needs for care and supportive services are assessed and priori-
tized and clients are provided with assistance (e.g., setting up appointments, providing
transportation) in accessing services. Referral should also include follow-up efforts nec-
essary to facilitate initial contact with care and support service providers.
In this context, referral does not include ongoing support or management of the
referral or case management. Case management is generally characterized by an ongo-
ing relationship with a client that includes comprehensive assessment of medical and
psychosocial support needs, development of a formal plan to address needs, substantial
assistance in accessing referral services, and monitoring of service delivery.
Typical Referral Needs
Clients should be referred to services that are responsive to their priority needs and
appropriate to their culture, language, sex, sexual orientation, age, and developmental
level. Examples of these services include
• Prevention case management. Clients with multiple and complex needs that affect
their ability to adopt and sustain behaviors to reduce their risk for transmitting or
acquiring HIV should receive or be referred for prevention case management
services, including ongoing prevention counseling (28 ). Prevention case
management can help coordinate diverse referral and follow-up concerns.
• Medical evaluation, care, and treatment. HIV-infected clients should receive or be
referred to medical services that address their HIV infection (including evaluation
of immune system function and screening, treatment, and prevention of
opportunistic infections) (23,29–32,53 ). Screening and prophylaxis for opportunis-
tic infections and related HIV-conditions (e.g., cervical cancer) are important for
HIV-infected persons. In addition, coinfection with HIV and communicable diseases
(e.g., TB, STDs, and hepatitis) can, if untreated, pose a risk to susceptible
community members. Thus, providers of HIV testing should be familiar with
appropriate screening tests (e.g., TB), vaccines (e.g., hepatitis A and B), STD and
prophylactic TB treatment, and clinical evaluation for active TB disease to ensure
that these communicable diseases are identified early and appropriate clinical
referrals are made, even if clients forego outpatient HIV treatment.
• Partner counseling and referral services. Persons with HIV-positive test results
should receive or be referred to services to help them notify their sex or injection-
drug-equipment–sharing partners or spouses regarding their exposure to HIV and
how to access CTR. Guidelines for PCRS are available (27 ).
• Reproductive health services. Female clients who are pregnant or of childbearing
age should receive or be referred to reproductive health services. HIV-infected
pregnant women should be referred to providers who can provide prevention
counseling and education, initiate medical therapy to prevent perinatal
transmission, and provide appropriate care based on established treatment
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guidelines (see Revised Recommendations for HIV Screening of Pregnant
Women ).
• Drug or alcohol prevention and treatment. Clients who abuse drugs or alcohol
should receive or be referred to substance or alcohol abuse prevention and
treatment services.
• Mental health services. Clients who have mental illness, developmental disability,
or difficulty coping with HIV diagnosis or HIV-related conditions should receive or
be referred to appropriate mental health services.
• Legal services. Clients who test positive should be referred to legal services as
soon as possible after learning their test result for counseling on how to prevent
discrimination in employment, housing, and public accommodation by only
disclosing their status to those who have a legal need to know.
• STD screening and care. Clients who are HIV-infected or at increased risk for HIV
are at risk for other STDs and should receive or be referred for STD screening and
treatment (146 ).
• Screening and treatment for viral hepatitis. Many clients who are HIV-infected or
at increased risk for HIV are at increased risk for acquiring viral hepatitis (A, B, and
C). Men who have sex with men and IDUs should be vaccinated for hepatitis A. All
clients without a history of hepatitis B infection or vaccination should be tested for
hepatitis B, and if not infected, should receive or be referred for hepatitis B
vaccination. In addition, clients who inject drugs should be routinely recommended
testing for hepatitis C. All clients who are infected with hepatitis viruses should be
referred for appropriate treatment. Further guidance is available (30,32 ).
• Other services. Clients might have multiple needs that can be addressed through
other HIV prevention and support services (e.g., assistance with housing, food,
employment, transportation, child care, domestic violence, and legal services).
Addressing these needs can help clients access and accept medical services and
adopt and maintain behaviors to reduce risk for HIV transmission and acquisition.
Clients should receive referrals as appropriate for identified needs.
Implement and Manage Referral Services
Clients should receive help accessing and completing referrals, and completion of
referrals should be verified. In the context of HIV prevention counseling and testing, the
following elements should be considered essential to the development and delivery of
referral services (99 ).
Assess Client Referral Needs
Providers should consult with the client to identify essential factors that a) are likely to
influence the client’s ability to adopt or sustain behaviors to reduce risk for HIV transmis-
sion or acquisition or b) promote health and prevent disease progression. Assessment
should include examination of the client’s willingness and ability to accept and complete
a referral. Service referrals that match the client’s self-identified priority needs are more
likely to be successfully completed than those that do not (147 ). Priority should be placed
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on ensuring that HIV-infected clients are assessed for referral needs related to medical
care, PCRS, and prevention and support services aimed at reducing the risk for further
transmission of HIV. When a provider cannot make appropriate referrals or when client
needs are complex, clients should be referred to a case management system.
Plan the Referral
Referral services should be responsive to clients’ needs and priorities and appropri-
ate to their culture, language, sex, sexual orientation, age, and developmental level. In
consultation with clients, providers should assess and address any factors that make
completing the referral difficult (e.g., lack of transportation or child care, work schedule,
cost). Research has indicated that referrals are more likely to be completed if services
are easily accessible to clients (147 ).
Help Clients Access Referral Services
Clients should receive information necessary to successfully access the referral ser-
vice (e.g., contact name, eligibility requirements, location, hours of operation, telephone
number). Research has indicated that providing assistance (e.g., setting an appointment,
addressing transportation needs) for some clients promotes completion of referrals
(148 ). Clients must give consent before identifying information to help complete the
referral can be shared. Outreach workers and peer counselors/educators can be an
important and effective resource to help clients identify needs and plan successful refer-
rals (149 ). Referrals are more likely to be completed after multiple contacts with out-
reach workers (147 ).
Document Referral and Follow-Up
Providers should assess and document whether the client accessed the referral ser-
vices. If the client did not, the provider should determine why; if the client did, the provider
should determine the client’s degree of satisfaction. If the services were unsatisfactory,
the provider should offer additional or different referrals. Documentation of referrals
made, the status of those referrals, and client satisfaction with referrals should help
providers better meet the needs of clients. Information obtained through follow-up of
referrals can identify barriers to completing the referral, responsiveness of referral
services in addressing client needs, and gaps in the referral system.
Ensure High-Quality Referral Services
Providers of referral services should know and understand the service needs of their
clients, be aware of available community resources, and be able to provide services in a
manner appropriate to the clients’ culture, language, sex, sexual orientation, age, and
developmental level, given local service system limitations.
Education and Support of Staff Members
Staff members providing referral services must understand client needs, have skills
and resources to address these needs, have authority to help the client procure services,
and be able to advocate for clients.
Training and Education. Providers should ensure that staff members receive
adequate training and continuing education to implement and manage referrals. Training
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and education should address resources available and methods for managing referrals,
as well as promote understanding of factors likely to influence the client’s ability and
willingness to use a referral service (e.g., readiness to accept the service, competing
priorities, financial resources). Referrals are more likely to be completed when a pro-
vider is able to correctly evaluate a client’s readiness to adopt risk-reducing behaviors
(147 ). Research has indicated that cross-training increases knowledge and understand-
ing of community resources among providers and can indicate gaps in services (148 ).
Authority. Staff members providing referrals must have the authority necessary to
accomplish a referral. Supervisors must ensure that staff members understand referral
policy and protocol and have the necessary support to provide referrals. This requires
the authority of one provider to refer to another (e.g., through memoranda of agree-
ment) or to obtain client consent for release of medical or other personal information.
Advocacy. Staff members who negotiate referrals must possess knowledge and skills
to advocate for clients. Such advocacy can help clients obtain services by mediating
barriers to access to services and promoting an environment in which providers are
better informed regarding the needs and priorities of their clients.
Provider Coordination and Collaboration
Providers should develop and maintain strong working relationships with other pro-
viders and agencies that might be able to provide needed services. Providers who offer
HIV prevention counseling and testing but not a full range of medical and psychosocial
support services should develop direct, clearly delineated arrangements with other pro-
viders who can offer needed services. Coordination and collaboration promotes a shared
understanding of the specific medical and psychosocial needs of clients requiring ser-
vices, current resources available to address these needs, and gaps in resources.
Memoranda of agreement or other forms of formal agreement are useful in outlining
provider/agency relationships and delineating roles and responsibilities of collaborating
providers in managing referrals. When confidential client information is shared between
coordinating providers, such formal agreements are essential. These agreements should
be reviewed periodically and modified as appropriate.
Referral Resources
Knowledge of available support services is essential for successful referrals. When
referral resources are not available locally, providers should identify appropriate
resources and link clients with them. A resource guide should be developed and main-
tained to help staff members make appropriate referrals (Box 7). Information regarding
community resources can be obtained from local health planning councils, consortia, and
community planning groups. Local, state, and national HIV/AIDS information hotlines or
websites (e.g., NPIN), community-based health and human service providers, and state
and local public health departments can also provide information.
HIV CTR SERVICES IN NONTRADITIONAL SETTINGS
CTR should be provided in community-based and outreach settings as well as clinical
settings. Data from publicly supported CTR programs have indicated that doing so could
promote use of these services by persons at increased risk for HIV. When HIV CTR are not
readily available, accessible, or acceptable, persons at increased risk might not take
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BOX 7. Contents of a referral resource guide
For each resource, the referral resource guide should specify the following:
• Name of the provider or agency
• Range of services provided
• Target population
• Service area(s)
• Contact names and telephone and fax numbers, street addresses, e-mail
addresses
• Hours of operation
• Location
• Competence in providing services appropriate to the client’s culture, language,
sex, sexual orientation, age, and developmental level
• Cost for services and acceptable methods of payment
• Eligibility
• Application materials
• Admission policies and procedures
• Directions, transportation information, and accessibility to public transportation
• Client satisfaction with services
advantage of them. Expanding CTR into nontraditional settings can be accomplished
through partnership with community-based service providers and use of new, FDA-
approved HIV test technologies that offer portability, less-invasive sample collection,
less-complex sample collection and processing, and reduced biohazard. To ensure effec-
tive CTR that is responsive to client needs, providers should develop and implement
written quality assurance protocols and procedures specifically for services provided in
nontraditional settings.
Privacy and Confidentiality
 Ensuring clients’ privacy and confidentiality during CTR is essential, but could present
unique challenges in some nontraditional settings. Confidentiality can more easily be
breached in settings where clients and providers can be seen or heard by others. Sug-
gested strategies for maintaining privacy and confidentiality in nontraditional settings
include the following:
• Use a separated area in a mobile van.
• Use rooms with locking doors.
Vol. 50 / No. RR-19 MMWR 41
• Mark a specific room with a “do not disturb” or “occupied” sign.
• Designate an area in the setting that provides physical privacy.
• In parks and similar locations, seek areas with as much privacy as possible.
• Provide counseling and testing services in the client’s home or other secure setting.
• Have clients return to the setting to receive test results and counseling and
referral.
Informed Consent
Staff members providing CTR services should be sensitive to barriers that can inter-
fere with obtaining true informed consent, including alcohol and drug use, mental illness,
and peer pressure in venues where persons congregate or socialize. Suggested strate-
gies for obtaining informed consent in nontraditional settings include the following:
• Schedule an appointment to test at a later date/time.
• Follow up at a later time with the client if contact information is available.
• Read the informed consent form to the client.
• Use verbal prompts to ensure that the client understands information in the
informed consent form.
Counseling
Staff members working in community-based and other nontraditional settings should
know and use risk-screening strategies to determine whether HIV prevention counseling
should be recommended. Staff members should be trained in HIV prevention counseling
or other approaches aimed at personal HIV risk reduction. When appropriate (e.g., among
IDUs), information regarding other STDs and bloodborne diseases should be incorpo-
rated into the counseling sessions (29,30 ).
Testing
The decision to offer HIV testing in nontraditional settings should be based on several
factors, including availability of resources and feasibility of providing test results and
follow-up. In some cases, referral to other providers is appropriate. The selection of a
specific HIV test technology should be based on logistical issues (e.g., field conditions
related to collection, transport, and storage of specimens; worker safety; and the likeli-
hood that clients will receive HIV test results). Providers must understand the extent to
which field conditions can affect specimens (e.g., extreme temperatures or time lapse
from collection to processing). Test specimens should be collected, stored, and trans-
ported according to manufacturer instructions.
Provision of Test Results
Clear protocols for provision of test results and prevention counseling should be
developed. The following strategies might be useful in ensuring the provision of results in
nontraditional settings:
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• Provide a telephone number that clients can call to receive test results.
• Make an appointment with the client at the time of testing to receive results.
• Provide incentives (e.g., food certificates, hygiene kits, food).
• Return to a site on a regularly scheduled basis.
• Provide reminders when contact information is available.
Referral
Staff members working in community-based and outreach settings should be trained
to implement and manage referrals. Providers should establish appropriate collabora-
tive relationships for referrals. Arranging for PCRS staff members or case managers to
be available to clients at the time test results are provided might help promote referral.
Record Keeping
Maintaining the confidentiality of client records is critical. Providers should develop
written protocols for record keeping that address transport of client records to and from
outreach venues. Strategies to maintain confidentiality of client records in nontraditional
settings include the following:
• Return all client records to the office immediately after the CTR session.
• Use codes or unique identifiers rather than client names.
• Store all records in a secured area (e.g., locked file drawers).
• Provide option of anonymous counseling and testing as well as confidential
counseling and testing.
• Verify identity of client (e.g., match client signature with that provided for informed
consent or check identification card) when providing test results.
• Store paperwork in a lockbox while in outreach settings.
• Password protect and encrypt electronically stored client records.
Where allowed by state/local statute, clients can choose anonymous HIV testing.
Procedures to ensure client anonymity (i.e., no indication of testing in the client’s record
and no recording of personal identifying information on laboratory requests) should be
developed. Even when staff members providing CTR services know the client (including
name and locating information) from other activities, the client’s right to be tested anony-
mously should be protected.
Staff Safety
Providing services in outreach settings (e.g., bars, parks) might compromise staff
safety, which must be considered in development of outreach protocols. Appropriate
training and precautions (e.g., working in teams) should be developed in planning ser-
vices in nontraditional settings.
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QUALITY ASSURANCE AND EVALUATION
OF HIV CTR SERVICES
Quality Assurance
Written quality assurance protocols should be developed, made available to all staff
members providing CTR services, and routinely implemented. All staff members should
receive training and orientation regarding quality assurance. For information specific to
ensuring high-quality CTR services, see Ensuring High-Quality HIV Prevention Counsel-
ing, Ensuring High-Quality Testing, and Ensuring High-Quality Referral Services. Quality
assurance activities should address the following:
• Accessibility of services (e.g., hours of operation, location, availability of supplies
and materials such as brochures, posters, test kits, safe injection materials,
condoms, or lubricant).
• Compliance with written protocols for provision of service to an individual client
(e.g., appropriate counseling protocols, timely return of HIV test results, referral for
services responsive to client’s priority needs).
• Services and materials appropriate to the client’s culture, language, sex, sexual
orientation, age, and developmental level.
• Staff performance/proficiency (e.g., competence, skills, credentials, and training).
• Supervision of staff members, including routine, timely feedback.
• Compliance with program guidelines and performance standards.
• Appropriateness of services to client needs, measured with client satisfaction tools
(e.g., surveys or suggestion boxes).
• Record-keeping procedures, including confidentiality and security.
• Community resources (availability and collaborative arrangements).
• Collection, handling, and storage of specimens.
• Assurance of adequate funding and institutional support for CTR services.
Evaluation
CTR services should be continually evaluated to improve services to clients and pro-
vide accountability to stakeholders (150,151 ). Evaluation should be interactive, involv-
ing individual persons and organizations affected by the services (150 ). In public health
settings, the community goals outlined in community health planning processes and
other relevant local planning processes could be incorporated.
Providers should identify the key, relevant program goals and objectives that reflect
services to the program, community, and client, and then determine what data are needed
to evaluate those goals and objectives. Information obtained from the evaluation should
be used to plan and prioritize provision of CTR services within a setting. For example,
information from the HIV Counseling and Testing System (133 ) or locally available
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sources could be used during local community planning (e.g., HIV prevention community
planning) to help develop or revise an HIV/AIDS prevention plan or describe who needs
services. If resources for evaluation are limited, comprehensive evaluations (e.g., exam-
ining outcome or impact) might not be possible. However, even with limited resources,
providers can conduct meaningful evaluations by focusing on relevant local
outcomes (82 ).
Data
Data collected should have a clear, anticipated use and should not be the focus of or
interfere with provision of CTR services. Data should be used to evaluate the extent to
which the goals of CTR and locally defined service outcomes (e.g., targeted return rates,
knowledge of HIV infection status, proportion of successful referrals) are met. Although
sound data are essential for evaluation of services, the primary purpose of each visit
should be to provide the best possible service to the client. Data should be recorded
outside the time reserved for CTR discussions between the provider and the client.
Clients could complete a questionnaire or intake information form on admission, provid-
ers could complete the forms immediately after meeting with a client, or a combination of
the two approaches could be used.
Data collection methods should be compatible with the evaluation needs and priori-
ties of the CTR setting and locally defined service outcomes. Data should be collected
with a standard collection instrument throughout the program. Simple data collection
instruments (e.g., intake forms, medical record reviews) should be developed so data
can be collected unobtrusively as part of the provision of services.
Publicly funded CTR sites collect data on client demographic characteristics, risk
behavior/exposure category, test acceptance, and type of site where service is provided
(133 ). Most sites record the date of visit, anonymous or confidential test status, previous
test result, current test result, and return for current test result for each client encounter.
Additional data can be useful for evaluation of services, including date of previous test,
type of current test (e.g., standard, rapid, oral fluid), risk-reduction plan summary, infor-
mation relevant to any referrals made (e.g., provider and service description, informa-
tion and materials provided, whether an appointment was made), whether the referral
was received, type of service provided, dates when services were provided, and other
relevant information (e.g., follow-up required, additional service needs).
Confidentiality
Any data collected or recorded must be collected or recorded in a manner that en-
sures the confidentiality of the client. Clear procedures and protocol manuals must be
developed and used.
Ensuring High-Quality Evaluation
• The system used to collect the information must be monitored periodically to
ensure data quality, which depends on the cooperative efforts of all persons
providing CTR services. Periodically, data collection systems should check records
at each level of the data-collection process to ensure that information is recorded
consistently and completely.
Vol. 50 / No. RR-19 MMWR 45
• Adequate training in the use of data collection instruments should be provided to all
staff members to ensure that the evaluation process is not interfering with the
provision of high-quality CTR services.
• The information assembled during the evaluation process should be analyzed and
reported in a timely manner to individual persons and organizations affected by the
service.
• Information and feedback gained during the evaluation process should be used to
improve the services offered by the site to the client.
CONCLUSION
Advances in HIV prevention and medical treatment increase the importance of HIV
CTR services. Prevention counseling and knowledge of HIV status can help persons who
are HIV-infected or at increased risk for HIV infection reduce their risk for transmitting or
acquiring HIV infection. Referral can help persons access relevant medical, preventive,
and psychosocial support services to reduce their risk for transmitting or acquiring HIV
infection. These guidelines recommend how CTR can be provided to clients who could
most benefit from these services across various settings and client populations.
ADDITIONAL RESOURCES
Additional information on HIV CTR can be obtained from the following sources:
• CDC’s National Center for HIV, STD, and TB Prevention website at <http://
www.cdc.gov/nchstp/od/nchstp.html>.
• CDC National AIDS Hotline in English, (800) 342-2437.
• CDC National AIDS Hotline in Spanish, (800) 344-7432.
• CDC National AIDS Hotline TTY, (800) 243-7889.
• CDC National STD Hotline, (800) 227-8922.
• CDC’s National Prevention Information Network at <http://www.cdcnpin.org> or
(800) 458-5231 (information available in English and Spanish).
• HIV/AIDS Treatment Information Service at <http://www.hivatis.org> or (800) 448-
0440 (information available in English and Spanish).
• AIDS Clinical Trials Information Service at <http://www.actis.org> or (800) 874-
2572 (information available in English and Spanish).
• National Clinicians’ Post-Exposure Prophylaxis Hotline at <http://pepline.ucsf.edu/
PEPline> or (888) 448-4911.
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Glossary
AIDS: Acquired immunodeficiency syndrome. AIDS can affect the immune and central
nervous systems and can result in neurological problems, infections, or cancers. It is
caused by human immunodeficiency virus (HIV).
Anal sex: A type of sexual intercourse in which a man inserts his penis in his partner’s
anus. Anal sex can be insertive or receptive.
Anonymous: In anonymous testing, client identifying information is not linked to testing
information, including the request for tests or test results.
Antiretroviral therapy: Treatment with drugs designed to prevent HIV from replicating in
HIV-infected persons. Highly active antiretroviral therapy (HAART) is an antiretroviral
regimen that includes multiple classifications of antiretroviral drugs.
Client-centered HIV prevention counseling: An interactive risk-reduction counseling
model usually conducted with HIV testing, in which the counselor helps the client
identify and acknowledge personal HIV risk behaviors and commit to a single, achiev-
able behavior change step that could reduce the client’s HIV risk.
Confidentiality: Pertains to the disclosure of personal information in a relationship of
trust and with the expectation that it will not be divulged to others in ways that are
inconsistent with the original disclosure. Confidentiality must be maintained for per-
sons who are recommended and/or who receive HIV counseling, testing, and refer-
ral (CTR) services.
Confidential HIV test: An HIV test for which a record of the test and the test results are
recorded in the client’s chart.
Confirmatory test: A highly specific test designed to confirm the results of an earlier
(screening) test. For HIV testing, a Western blot or, less commonly, an immunofluo-
rescence assay (IFA) is used as a confirmatory test.
EIA: Enzyme immunoassay. Sometimes referred to as ELISA (see next definition). A
commonly used screening test to detect antibodies to HIV.
ELISA: Enzyme-linked immunosorbent assay. A type of EIA (see previous definition). A
commonly used screening test to detect antibodies to HIV.
Evaluation: A process for determining how well health systems, either public or
private, deliver or improve services and for demonstrating the results of resource
investments.
False negative: A negative test result for a person who is actually infected.
False positive: A positive test result for a person who is actually not infected.
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Freestanding HIV test site: A site that provides only HIV services. Sometimes
referred to as alternate test site or anonymous test site.
HIV: Human immunodeficiency virus, which causes AIDS. Several types of HIV exist,
with HIV-1 being the most common in the United States.
HIV test: More correctly referred to as an HIV antibody test, the HIV test is a laboratory
procedure that detects antibodies to HIV, rather than the virus itself.
HIV prevention counseling: An interactive process between client and counselor aimed
at reducing risky sex and needle-sharing behaviors related to HIV acquisition (for
HIV-uninfected clients) or transmission (for HIV-infected clients). See also client-
centered HIV prevention counseling.
Home sample collection test: A test that a consumer purchases and uses to collect blood
(or other bodily fluid) and then send it out for testing. Counseling and test results are
typically provided by telephone using user-generated codes to ensure confidential-
ity and anonymity.
Incidence: In epidemiology, the number of new cases of infection or disease that occur in
a defined population within a specified time.
Indeterminate test result: A possible result of a Western blot, which might represent a
recent HIV infection or a false-positive.
Information: In the context of HIV counseling, information encompasses the topics HIV
transmission and prevention and the meaning of HIV test results.
Informed consent: The legally effective permission of a client or legally authorized repre-
sentative (e.g., parent or legal guardian of a minor child) to undergo a medical test or
procedure.
Negative predictive value: A negative predictive value estimates the probability that a
person with a negative diagnostic test result will actually not be infected.
Nonoccupational HIV exposure: A reported sexual, injection-drug–use, or other non-
occupational HIV exposure that might put a patient at high risk for acquiring HIV
infection.
Nucleic acid amplification testing: A type of testing that identifies viral genes (e.g., spe-
cific sequences of nucleic acids) using gene amplification technologies such as poly-
merase chain reaction (PCR).
Occupational HIV exposure: An occupational exposure to HIV that occurs during the
performance of job duties. Defined as a percutaneous injury (e.g., a needlestick or
cut with a sharp object), contact of mucous membranes, or contact of skin (especially
when the exposed skin is chapped, abraded, or afflicted with dermatitis or the con-
tact is prolonged or involving an extensive area) with blood, tissues, or other body
fluids to which universal precautions apply.
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Oral fluid test: A test using oral mucosal transudate, a serous fluid. To differentiate this
fluid from saliva, an absorbent material is left in the mouth for several minutes. In an
HIV-infected person, oral mucosal transudate is likely to contain HIV antibodies.
Oral sex: A type of sexual intercourse in which the partner’s genitals are stimulated by
mouth and tongue.
Partner counseling and referral services (PCRS): A prevention activity that aims to
a) provide services to HIV-infected persons and their sex and needle-sharing part-
ners so they can reduce their risk for infection or, if already infected, can prevent
transmission to others and b) help partners gain earlier access to individualized
counseling, HIV testing, medical evaluation, treatment, and other prevention and
support services.
Perinatal HIV transmission: Transmission of HIV from the mother to the fetus or infant
during pregnancy, delivery, or breast-feeding.
Positive predictive value: A positive predictive value estimates the probability that a
person with a positive diagnostic test result will actually be infected.
Positive test: For HIV, a specimen sample that is reactive on an initial ELISA test, repeat-
edly reactive on a second ELISA run on the same specimen, and confirmed positive
on Western blot or other supplemental test indicates that the client is infected.
Prevalence: The number or percentage of persons in a given population with a
disease or condition at a given point in time.
Prevention case management (PCM): A client-centered HIV prevention activity that pro-
motes adoption of HIV risk-reduction behaviors by clients with multiple, complex
problems and risk-reduction needs. PCM is a hybrid of HIV prevention counseling
and traditional case management that provides intensive, on-going, individualized
prevention counseling, support, and referral to other needed services.
Prevention counseling: An interactive process between client and counselor aimed at
reducing risky sex and needle-sharing behaviors related to HIV acquisition (for HIV-
uninfected clients) or transmission (for HIV-infected clients). See also client-centered
HIV prevention counseling and HIV prevention counseling.
Quality assurance: An ongoing process for ensuring that the CTR program effectively
delivers a consistently high level of service to the clients.
Rapid HIV test: A test to detect antibodies to HIV that can be collected and processed
within a short interval of time (e.g., approximately 10–60 minutes).
Referral: The process through which a client is connected with services to address pre-
vention needs (medical, prevention, and psychosocial support).
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Risk assessment: Risk assessment is a fundamental part of a client-centered HIV preven-
tion counseling session in which the client is encouraged to identify, acknowledge,
and discuss in detail his or her personal risk for acquiring or transmitting HIV.
Risk screening: A brief evaluation of HIV risk factors, both behavioral and clinical, used
for decisions about who should be recommended HIV counseling and testing. Risk
screening is different from risk assessment.
Screening test: An initial test, usually designed to be sensitive, to identify all persons with
a given condition or infection (e.g., enzyme immunoassay [EIA] or enzyme-linked
immunosorbent assay [ELISA]).
Sensitivity: The probability that a test will be positive when infection or condition is
present.
Seroconversion: Initial development of detectable antibodies specific to a particular
antigen; the change of a serologic test result from negative to positive as a result of
antibodies induced by the introduction of antigens or microorganisms into the host.
Specificity: The probability that a test will be negative when the infection or condition is
not present.
Tuberculosis (TB) disease: Active disease caused by Mycobacterium tuberculosis, as
evidenced by a confirmatory culture, or, in the absence of culture, suggestive clinical
symptoms, including productive cough lasting >3 weeks, chest pain, hemoptysis,
fever, night sweats, weight loss, and easy fatigability. Active TB is a communicable
disease that is treatable, curable, and preventable, and persons with active TB dis-
ease should be under the care of a health-care provider. Active TB disease could
indicate immune deficiency. For HIV-infected persons, active TB disease is consid-
ered an opportunistic infection and a qualifying condition for AIDS.
Tuberculosis (TB) infection: Infection with the bacteria M. tuberculosis, as evidenced by a
positive tuberculin skin test (TST) that screens for infection with this organism. Some-
times, TST is called a purified protein derivative (PPD) or Mantoux test. A positive
skin test might or might not indicate active TB disease (see tuberculosis disease).
Thus, any person with a positive TST should be screened for active TB and, once
active TB is excluded, evaluated for treatment to prevent the development of TB
disease. TB infection alone is not considered an opportunistic infection indicating
possible immune deficiency.
Vaginal sex: A type of sexual intercourse in which the man’s penis enters the woman’s
vagina.
Voluntary HIV testing: HIV testing that is offered free of coercion. With voluntary HIV
testing, participants have the opportunity to accept or refuse HIV testing.
Western blot: A laboratory test that detects specific antibodies to components of a virus.
Chiefly used to confirm HIV antibodies in specimens found repeatedly reactive using
ELISA.
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EXPIRATION — November 9, 2004
You must complete and return the response form electronically or by mail by November 9, 2004, to receive
continuing education credit. If you answer all of the questions, you will receive an award letter for 2.75 hours
Continuing Medical Education (CME) credit, 0.25 hour Continuing Education Units (CEUs), or 3.1 hours
Continuing Nursing Education (CNE) credit. If you return the form electronically, you will receive educational
credit immediately. If you mail the form, you will receive educational credit in approximately 30 days. No fees are
charged for participating in this continuing education activity.
INSTRUCTIONS
By Internet
1. Read this MMWR (Vol. 50, RR-19, Revised Guidelines for HIV Counseling, Testing, and Referral ), which
contains the correct answers to the questions beginning on the next page.
2. Go to the MMWR Continuing Education Internet site at <http://www.cdc.gov/mmwr/cme/conted.html>.
3. Select which exam you want to take and select whether you want to register for CME, CEU, or CNE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must answer all of the questions.
Questions with more than one correct answer will instruct you to “Indicate all that apply.”
6. Submit your answers no later than November 9, 2004.
7. Immediately print your Certificate of Completion for your records.
By Mail or Fax
1. Read this MMWR (Vol. 50, RR-19, Revised Guidelines for HIV Counseling, Testing, and Referral ), which
contains the correct answers to the questions beginning on the next page.
2. Complete all registration information on the response form, including your name, mailing address, phone
number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive
continuing education credit, you must answer all of the questions. Questions with more than one correct
answer will instruct you to “Indicate all that apply.”
5. Sign and date the response form or a photocopy of the form and send no later than November 9, 2004, to
Fax:  404-639-4198 Mail: MMWR CE Credit
Office of Scientific and Health Communications
Epidemiology Program Office, MS C-08
Centers for Disease Control and Prevention
1600 Clifton Rd, N.E.
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.
ACCREDITATION
Continuing Medical Education (CME). CDC is accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to provide continuing medical education for physicians. CDC designates this educational activity for a maximum
of 2.75 hours in category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those
hours of credit that he/she actually spent in the educational activity.
Continuing Education Unit (CEU). CDC has been approved as an authorized provider of continuing education and training
programs by the International Association for Continuing Education and Training and awards 0.25 hour Continuing
Education Units (CEUs).
Continuing Nursing Education (CNE). This activity for 3.1 contact hours is provided by CDC, which is accredited as a
provider of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation.
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GOAL AND OBJECTIVES
This MMWR provides recommendations regarding human immunodeficiency virus (HIV) counseling, testing,
and referral (CTR). These recommendations were prepared by CDC using an evidence-based approach
advocated by the U.S. Preventive Services Task Force and public health practice guidelines. The goal of this
report is to provide guidance to public- and private-sector policy makers and service providers on HIV CTR. Upon
completion of this continuing education activity, the reader should be able to a) identify the goals of HIV
counseling, testing, and referral, b) describe the primary focus and essential elements of HIV prevention
counseling, c) describe the factors that determine who should be offered an HIV test, and d) identify the factors
that should be considered when determining the timing of follow-up HIV testing.
To receive continuing education credit, please answer all of the following questions.
1. Which of the following are goals of HIV CTR?
A. Ensure that HIV-infected persons and persons at increased risk for HIV have access to
HIV testing to promote early knowledge of their HIV status.
B. Ensure that HIV-infected persons and persons at increased risk for HIV receive high-
quality HIV prevention counseling to reduce their risk for transmitting or acquiring HIV.
C. Ensure that HIV-infected persons and persons at increased risk for HIV have access to
appropriate medical, preventive, and psychosocial support services.
D. All of the above.
2. HIV counseling conducted along with HIV testing serves the following purposes:
A. Provides information regarding how HIV infection is transmitted and prevented, the
importance of obtaining test results, and the meaning of HIV test results.
B. Helps clients identify HIV risks and commit to steps to reduce their risks for acquiring or
transmitting HIV infection.
C. Both A and B.
D. None of the above.
3. The primary focus of HIV prevention counseling is to . . .
A. ensure that the counseling is sensitive to the client’s culture, language, sex, sexual
orientation, age, and developmental level.
B. remain respectful of the client and maintain a nonjudgmental approach.
C. ensure that the client fully interacts with the counselor in the counseling session.
D. reduce the client’s personal risk for HIV acquisition or transmission.
4. Essential elements of HIV prevention counseling include all of the following except:
A. Keep the session focused on HIV risk reduction.
B. Include an in-depth, personalized risk assessment.
C. Acknowledge and provide support for HIV prevention steps already taken.
D. Ensure that all of the client’s misconceptions regarding HIV infection, including those
not related to the client’s personal risk, are clarified.
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5. Procedures that help ensure high-quality HIV prevention counseling include all of the
following except:
A. Training and continued education for counseling staff members.
B. Routine, periodic observation and feedback of counseling sessions.
C. Routine collection of key data elements for evaluation during the counseling session.
D. Support from supervisors and policy makers.
6. Anonymous testing for HIV infection is beneficial in the following ways:
A. Increasing the number of persons who know their HIV status.
B. Promoting follow-up.
C. Promoting earlier treatment.
D. All of the above.
7. Which of the following factors help determine who should be recommended an HIV test?
A. Behavioral HIV risk of client population.
B. HIV prevalence of population at facility.
C. Availability of effective treatment for HIV prevention (e.g., perinatal transmission).
D. All of the above.
8. Which of the following is the best definition of referral?
A. An ongoing relationship with a client that includes assessing a client’s medical and
psychosocial support needs and providing care for those needs.
B. A process in which a client’s need for medical, preventive, and supportive services is
assessed, and the client is assisted in accessing appropriate services.
C. An interactive process aimed at reducing risky behaviors related to HIV acquisition or
transmission.
D. An evaluation of risk factors for HIV infection used to make decisions regarding who
should be offered HIV testing.
9. Which statement is true regarding counseling, testing, and referral services in
nontraditional settings (e.g., community-based and outreach settings)?
A. These services could benefit from the use of new HIV test technologies.
B. These services require quality assurance protocols and procedures tailored specifically
for these settings.
C. These services help reach persons at increased risk for HIV infection.
D. All of the above.
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10. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.




D. Patient care — private medical setting.
E. Client care — publicly funded site.
F. Public health.
12. I plan to use these guidelines as the basis for . . . (Indicate all that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.







14. How much time did you spend reading this report and completing the exam?
A. Fewer than 1.5 hours.
B. More than 1.5 hours but fewer than 2 hours.
C. 2–2.5 hours.
D. More than 2.5 hours but fewer than 3 hours.
E. 3 hours or more.
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C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can describe the primary focus and essential
elements of HIV prevention counseling.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can describe the factors that determine who
should be offered an HIV test.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can identify the factors that should be considered
when determining the timing of follow-up HIV testing.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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20. The tables and figures are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. How did you learn about this continuing education activity?
A. Internet.





Correct answers for questions 1–9
1. D; 2. C; 3. D; 4. D; 5. C; 6. D; 7. D; 8. B; 9. D.
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Revised Recommendations for HIV Screening
of Pregnant Women
Summary
These guidelines replace CDC’s 1995 guidelines, U.S. Public Health Service
Recommendations for Human Immunodeficiency Virus Counseling and Voluntary
Testing for Pregnant Women, and are for public- and private-sector service
providers who provide health care for pregnant women. In 1998, the Institute of
Medicine (IOM) published a report that recommended simple, routine, and
voluntary human immunodeficiency virus (HIV) testing for all pregnant women in
antenatal settings, given the effective interventions available to treat HIV-infected
women and reduce risk for perinatal HIV transmission. In 1999, CDC convened
consultation groups to discuss and comment on the IOM report. These guidelines
are based on input from these meetings, the IOM report, and public comment on
draft guidelines published in Fall 2000 in the Federal Register. These guidelines
were also prompted by scientific and programmatic advances in the prevention of
perinatally acquired HIV and care of HIV-infected women. These recommenda-
tions are consistent with the Revised Guidelines for HIV Counseling, Testing, and
Referral.
Major revisions from the 1995 guidelines include
• emphasizing HIV testing as a routine part of prenatal care and strengthening
the recommendation that all pregnant women be tested for HIV;
• recommending simplification of the testing process so that pretest
counseling is not a barrier to testing;
• making the consent process more flexible to allow for various types of
informed consent;
• recommending that providers explore and address reasons for refusal of
testing; and
• emphasizing HIV testing and treatment at the time of labor and delivery for
women who have not received prenatal testing and antiretroviral drugs.
These guidelines recommend voluntary HIV testing to preserve a woman’s
right to participate in decisions regarding testing to ensure a provider-patient
relationship conducive to optimal care for mothers and infants and to support a
woman’s right to refuse testing if she does not think it is in her best interest.
INTRODUCTION
In 1994, after the announcement of the results of Pediatric AIDS Clinical Trials Group
(PACTG) protocol 076 (1 ), the Public Health Service (PHS) published guidelines for
zidovudine (ZDV) use to reduce perinatal human immunodeficiency virus (HIV) transmis-
sion (2 ). In 1995, PHS issued guidelines recommending universal counseling and volun-
tary HIV testing of all pregnant women and treatment for those infected (3 ). Publication
of these recommendations was followed by rapid implementation by health-care provid-
ers, widespread acceptance of chemoprophylaxis by HIV-infected women, and a steep
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and sustained decline in perinatal HIV transmission (4,5 ). Observational studies have
confirmed the effectiveness of ZDV in reducing the risk for perinatal transmission (6–8 ).
This reduction in transmission risk resulted in an 83% decline in perinatal acquired immu-
nodeficiency syndrome (AIDS) cases diagnosed in 1999, compared with the peak inci-
dence of 907 cases in 1992 (7 ).
Despite this progress, children are still being infected perinatally. CDC estimates that
280–370 infants are born with HIV infection each year in the United States (CDC, unpub-
lished data, 2000). These continued infections underscore the need for improved strate-
gies to ensure that all pregnant women are offered HIV testing and, if positive, treatment
to reduce their transmission risk and to safeguard their health and the health of their
infants.
Several lessons have been learned from evaluation of the 1995 PHS guidelines.
Many women, especially those who used illicit drugs, were not tested for HIV during
pregnancy because of lack of prenatal care (8 ). In addition, many women refused testing
because their health-care providers did not strongly recommend it. Some women
declined testing because of perceived low risk, and some providers failed to offer testing
because of perceived low risk, perceived difficulties and complexity of required counsel-
ing, and misunderstanding of counseling requirements. The logistics of testing, if too
complex, also were considered a potential barrier to testing.
In December 1998, the Institute of Medicine (IOM) completed a study commissioned
by Congress to assess the impact of current approaches for reducing perinatal HIV
transmission, identify barriers to further reductions, and determine ways to overcome
these barriers (9 ). IOM concluded that continued perinatal transmission was mainly
caused by a lack of awareness of HIV status among some pregnant women. This problem
was attributed to some health-care providers not offering HIV testing to all pregnant
women because the providers believed they could predict which women were most at
risk and that standard HIV testing protocols, particularly the requirement for extensive
pretest counseling, were too burdensome to conduct for all women. IOM concluded that
HIV testing should be simplified and made routine. They recommended that the United
States adopt a national policy of universal HIV testing, with patient notification, as a
routine component of prenatal care. That is, testing should be offered to all pregnant
women as part of the standard battery of prenatal tests, regardless of risk factors and the
prevalence rates in the community. IOM also recommended that women be informed
when an HIV test is conducted and of their right to refuse testing.
Since 1994–1995, major scientific advances in the prevention of perinatal transmis-
sion and the care of HIV-infected persons have occurred. These advances increased the
benefit of knowing one’s HIV status, especially during pregnancy. More effective treat-
ment has prolonged survival of HIV-infected persons and improved their quality of life
(10 ). Clinical trials proved the effectiveness of prophylactic therapy for preventing peri-
natal transmission in women who are not treated until the time of delivery (11 ). Studies
have indicated that women with nondetectable viral load rarely transmit HIV infection
(12–14 ). Finally, new testing technologies (e.g., rapid testing, urine sampling) offer new
options for HIV screening.
To address the lessons learned, IOM findings, and scientific advances, as well as the
causes of continued HIV infection in children, PHS convened specialists in the field in April
1999 and sought widespread public comment in revising the 1995 guidelines for HIV
counseling and testing for pregnant women. Consultation groups included researchers,
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professional health-care provider organizations (e.g., American Academy of Pediatrics,
American College of Obstetricians and Gynecologists), clinicians, women living with HIV,
and representatives from community organizations and PHS agencies overseeing care
of HIV-infected pregnant women.
The resulting guidelines are presented in this document. They differ from the 1995
guidelines in that they
• emphasize HIV testing as a routine part of prenatal care and strengthen the
recommendation that all pregnant women be tested for HIV,
• recommend simplifying the testing process so that pretest counseling is not a
barrier to testing,
• increase the flexibility of the consent process to allow for various types of informed
consent,
• recommend that providers explore and address reasons for refusal of testing, and
• emphasize HIV testing and treatment at the time of labor and delivery for women
who have not received prenatal testing and chemoprophylaxis.
These guidelines maintain a voluntary approach to HIV testing. This voluntary
approach preserves a woman’s right to make decisions regarding testing and supports a
woman’s right to refuse testing if she does not think it is in her best interest.
This document replaces the 1995 PHS guidelines (3 ). These recommendations are
primarily intended for providers of health care for women, with a focus on HIV screening
of pregnant women to reduce mother-to-child transmission of HIV. This report does not
address other concerns related to continued perinatal transmission (e.g., lack of prenatal
care). CDC programs targeted to states with the highest incidence of perinatal HIV infec-
tion address these ongoing public health problems (information on these programs is
available on the Internet at <http://www.cdc.gov/hiv/projects/perinatal/default.htm>).
Other PHS guidelines address the importance of prevention interventions, including test-
ing in the general population (see Revised Guidelines for HIV Counseling, Testing, and
Referral ). This report applies only to the United States; different recommendations,
especially on breast-feeding, will apply in other countries.
BACKGROUND
HIV Infection and AIDS in Women and Children
Of the approximately 750,000 AIDS cases reported to CDC through the end of 1999,
approximately 129,000 were in women. Approximately 64,000 women were living with
AIDS in 1999, a 31% increase from 1996, reflecting improved survival with new combi-
nation treatment regimens (15 ). However, women with AIDS represent only a fraction of
the number of HIV-infected women who need medical and social services. An estimated
120,000–160,000 HIV-infected women reside in the United States, 80% of whom are of
childbearing age (16 ).
Most women with HIV/AIDS in the United States reside in the Northeast and the
South. The highest numbers of cases were first observed in the Northeast, but the South
has reported the greatest increases in recent years. African-American and Hispanic
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women are disproportionately affected by the epidemic and account for 80% of AIDS
cases reported in U.S. women in 1999. Over time, the proportion of cases in women
attributable to injection-drug use has declined, whereas the proportion of cases from
heterosexual contact has increased, particularly among young women.
During 1985–1995, approximately 6,000–7,000 HIV-infected women gave birth in the
United States each year (7 ). During the early 1990s, before perinatal chemoprophylaxis
was available, an estimated 1,000–2,000 infants were born with HIV infection annually.
By June 2000, a total of 8,027 perinatally acquired AIDS cases were recorded nation-
wide, most (85%) in African-American and Hispanic children (7,15 ). Before the results of
the PACTG 076 trial using prenatal, intrapartum, and postpartum ZDV for perinatal pro-
phylaxis, the risk for mother-to-child transmission ranged from 16% to 25% in studies
from North America and Europe (17–19 ), up to 24% in Thailand (20 ), and 25–40% in
Africa (21,22 ). Worldwide, approximately 600,000 infants each year become infected
through mother-to-child transmission of the HIV virus.
In the United States, widespread implementation of the PHS guidelines for universal
counseling and testing and perinatal use of ZDV has sharply reduced transmission risk
and the number of perinatally acquired HIV infections (7 ). By 1995, several cohort stud-
ies had documented transmission rates of <11% (19,23 ). During 1996–2000, U.S. studies
indicated that transmission rates had declined to 5%–6% (12,24 ) and <1% in women
with nondetectable plasma viral loads (12,14,25 ). During 2000–2001, perinatal trans-
mission rates of <2% have been achieved with combination antenatal antiretroviral
drugs (26 ) or with ZDV combined with cesarean section (27–29 ). Analysis of U.S. peri-
natal AIDS surveillance data (15 ) reported through June 2000 indicated a sharp decline
in the number of perinatal AIDS cases; this decline was temporally associated with
increasing ZDV use among pregnant women aware of their HIV status (7 ). To more
accurately monitor trends in perinatal HIV transmission and the implementation and
impact of perinatal prevention programs (including HIV counseling and testing recom-
mendations), CDC, the Council of State and Territorial Epidemiologists (CSTE), and the
American Academy of Pediatrics (AAP) recommended national reporting of perinatal
HIV exposure and HIV infection to help identify and target populations where prevention
opportunities are missed (30,31 ).
Despite the declines, cases of perinatal HIV transmission continue to occur, largely
because of missed opportunities for prevention, particularly among women who lack
prenatal care or who are not being offered voluntary HIV counseling and testing during
pregnancy. The estimated 280–370 infants born with HIV infection each year represent
populations in which prevention efforts are impeded by lack of timely HIV testing and
treatment of pregnant women (7 ). Of 329 children with perinatally acquired AIDS born
during 1995–1996, a total of 112 (34%) were born to mothers not tested for HIV before
the child’s birth and 67 (20%) to mothers for whom the time of testing was not known.
Dynamics of Perinatal HIV Transmission
Perinatal transmission can occur during pregnancy (intrauterine), during labor and
delivery (intrapartum), or after delivery through breast-feeding (postpartum). In the
absence of breast-feeding, intrauterine transmission accounts for 25%–40% of infection,
and 60%–75% of transmission occurs during labor and delivery (32 ). Among women
who breast-feed, approximately 20%–25% of perinatal infections are believed to be
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associated with intrauterine transmission, 60%–70% with intrapartum transmission or
very early breast-feeding, and 10%–15% with later postpartum transmission through
breast-feeding (33 ). In a randomized trial of formula feeding versus breast-feeding,
approximately 44% of HIV infection was attributed to breast-feeding (34 ). In breast-
feeding populations, a shift toward an increasing proportion of transmission related to
breast-feeding is likely to occur as a consequence of successful preventive interventions
directed at late prenatal and intrapartum transmission.
Intrapartum transmission can occur during labor through maternal-fetal exchange of
blood or during delivery by contact of the infant’s skin or mucous membranes with
infected blood or other maternal secretions (32 ). Several studies have indicated that
most infections transmitted through breast-feeding probably occurred during the first
few weeks to months of life (34–36 ). Risk factors during breast-feeding include viral load
in breast milk (37,38 ), subclinical or clinical mastitis (37,39,40 ), breast abscesses (39,40 ),
and maternal seroconversion during the lactation period (39,41 ).
Several risk factors are associated with perinatal HIV transmission. Clinical factors
that increase the likelihood of transmission include immunologically or clinically advanced
HIV disease in the mother, high plasma viral load (12,25,42 ), maternal injection-drug use
during pregnancy, preterm delivery, nonreceipt of the PACTG 076 regimen, and breast-
feeding (32 ). No link has been established between perinatal HIV transmission and
maternal age, race/ethnicity, or history of having a previously infected child.
Obstetric factors also influence HIV transmission risk. The risk for perinatal trans-
mission increases per hour duration of membrane rupture after controlling for other risk
factors (43 ). Delivery >4 hours after the rupture of the fetal membranes can double the
risk for HIV transmission (19,44 ). Maternal infection with another sexually transmitted
disease (STD) during pregnancy and certain obstetrical procedures can also increase
risk (45 ). Chorioamnionitis (i.e., uterine infection) has been associated with an increased
risk for HIV transmission (23,46 ).
Most of these risk factors were identified before the recommended use of ZDV to
prevent perinatal HIV transmission. Their effects are unknown now that most pregnant
women infected with HIV are receiving ZDV chemoprophylaxis to prevent mother-to-
child transmission, as well as combination therapy for their own health. Because of the
sharp reductions in perinatal HIV transmission associated with effective antiretroviral
interventions, factors that interfere with women or their infants receiving ZDV treatment
(e.g., barriers to prenatal care, lack of HIV testing for some pregnant women) are increas-
ingly important (9 ).
Prevention of Perinatal Transmission
The birth of every perinatally HIV-infected infant is a sentinel health event signaling
either a missed prevention opportunity or, more rarely, a failure of prophylaxis. An
opportunity is missed whenever a woman of childbearing age is unaware of her HIV
status or her risk for HIV or when an HIV-infected pregnant woman a) does not receive
prenatal care, b) is not offered HIV testing, c) is unable to obtain HIV testing, d) is not
offered chemoprophylaxis, e) is unable to obtain chemoprophylaxis, or f) does not com-
plete the chemoprophylaxis regimen. Prophylaxis failures occur when an infant becomes
infected despite chemoprophylaxis and other preventive interventions (9 ). Each of these
missed opportunities or failures deserves attention from service providers and preven-
tion programs.
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Early Prenatal Care
Maximum reduction of perinatal transmission depends on preventing HIV infection in
women or identifying HIV infection before pregnancy or as early as possible during
pregnancy. Diagnosis allows a woman to receive effective antiretroviral therapies for
her own health and preventive drugs (e.g., ZDV) to improve the chances that her infant
will be born free of infection. Early knowledge of maternal HIV status is also important for
decisions regarding obstetrical management. Achieving these goals requires increased
access to and use of prenatal care.
Four states that conducted enhanced HIV surveillance reported that during 1993–
1996, approximately 15% of HIV-infected pregnant women in the United States received
no prenatal care, compared with only 2% of women in the general population (5 ). HIV-
infected women who used illicit drugs during pregnancy were at the highest risk for not
receiving prenatal care — 35% compared with 6% for HIV-infected women who were not
drug users. During 1997–1998, the HIV transmission rate among women in New York
State was 17.5% (30/171) among those with no prenatal care, 16.2% (23/142) among
those with 1–2 prenatal visits, and 8.0% (90/1,124) among those with >3 prenatal visits,
indicating the importance of prenatal care in providing services that prevent perinatal
transmission (47 ).
Offer and Acceptance of HIV Testing
Most women who have given birth since the 1995 PHS guidelines have received
information or counseling regarding HIV infection and have been offered testing. This
has occurred independently of state-to-state variations in application of recommended
practices, type of prenatal health-care provider, type of patient insurance, or maternal
demographic characteristics (9 ). A 14-state study of HIV counseling and testing data for
1996–1997 reported that the proportion of pregnant women voluntarily tested for HIV
was 58%–81% (30 ). Women most likely to receive HIV counseling and testing during
pregnancy were those who were African-American, had less than a high school educa-
tion, were aged <25 years, received care in public rather than private health-care set-
tings, and were Medicaid beneficiaries.
When offered, most women (approximately 70% in most settings) will accept HIV
testing. In a multicity study of prenatal clinic patients, 74%–95% of participants accepted
HIV testing (48 ). Reasons most commonly cited for acceptance were a) belief that knowl-
edge of positive HIV serostatus during pregnancy (and subsequent chemoprophylaxis)
can be beneficial to both mother and infant and b) strong provider endorsement for
prenatal HIV testing. The most common reasons for declining the test were no perceived
risk, administrative scheduling difficulties, history of previous testing, and lack of pro-
vider endorsement.
Although most providers agreed that all women should be tested for HIV, some
offered testing only to women whom they considered at risk for infection (49,50 ). Risk-
based testing approaches identified fewer HIV-infected women than routine voluntary
testing of all pregnant women (3 ) and also decreases in effectiveness as more women
are infected through heterosexual contact without knowing their partner’s HIV risk status.
Receipt of ZDV Chemoprophylaxis
The primary strategy to prevent perinatal transmission (in addition to avoidance of
breast-feeding) is antiretroviral chemoprophylaxis using ZDV, now often part of a com-
bined antiretroviral therapy regimen that reduces viral load as low as possible near the
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time of delivery. In the PACTG 076 protocol, chemoprophylaxis consisted of three compo-
nents: ZDV administered orally to the mother during the second and third trimesters of
pregnancy, intravenous administration of ZDV to the mother during labor and delivery,
and administration of oral ZDV to the infant during the first 6 weeks of life (1 ).
Data from several sources demonstrated rapid implementation of the recommenda-
tions for ZDV prophylaxis by health-care providers and use of ZDV by HIV-infected preg-
nant women. One study analyzed approximately 6,800 perinatally exposed and infected
children born during 1993–1998 in 32 states that reported HIV infection (51 ). Among
those whose mothers were tested for HIV before or at birth of the infant, the percentage
of infants receiving any component of the recommended ZDV regimen increased from
37% in 1994 to approximately 85% during 1996–1998. In a supplemental study of women
diagnosed before delivery in four states, the proportion offered prenatal ZDV increased
from 27% in 1993 to 85% in 1996, the proportion offered intrapartum ZDV increased
from 5% to 75%, and the proportion offered neonatal ZDV increased from 5% to 76% (5 ).
Fewer than 5% of women refused ZDV.
Abbreviated Antiretroviral Regimens
Given the complexity and cost of the PACTG 076 regimen, particularly for the devel-
oping world, other effective strategies to reduce the risk for perinatal HIV transmission
have been identified. Results of randomized clinical trials in developing countries and
observational data from the United States indicated that abbreviated perinatal
antiretroviral regimens (20,52–54 ), regimens that begin as late as the onset of labor
(11 ), and possibly antiretroviral chemoprophylaxis given only to the newborn (47 ) are
effective in reducing the risk for perinatal transmission.
Abbreviated antiretroviral regimens have also proved effective in reducing the risk
for transmission in resource-poor countries. In nonbreast-feeding women, a short
antepartum/intrapartum regimen of ZDV reduced transmission by 50% (20 ); a similar
regimen in breast-feeding populations was also effective, although efficacy was lower
(52–54 ). Two other intrapartum/postpartum antiretroviral regimens were effective in
reducing transmission in clinical trials among breast-feeding African women. One regi-
men was nevirapine given as a single dose to the woman in labor and to the infant at age
48 hours, and the other was ZDV plus lamivudine (3TC) given orally intrapartum and to
the infant and mother for 1 week postpartum (11,36,55 ). Observational data and animal
studies indicated that newborn prophylaxis alone offered some protection (24,56 ).
Updated recommendations for use of these regimens in the United States, including for
pregnant women who do not receive health care until near the time of delivery  are
available at the HIV/AIDS Treatment Information Service (ATIS) website at <http://
www.hivatis.org> (57 ).
Other Strategies to Prevent Perinatal Transmission
Reducing exposure of the infant to maternal blood and secretions during the intrapar-
tum period can prevent perinatal HIV transmission. Cesarean delivery performed before
onset of labor and membrane rupture lowers the risk for HIV transmission compared
with vaginal delivery in certain populations of women. Cesarean delivery resulted in a
50% reduction in perinatal HIV transmission overall among HIV-infected women who had
cesarean deliveries compared with women delivering vaginally (28 ). A randomized
clinical trial in Europe (27 ) demonstrated a benefit of elective cesarean section before
onset of labor for both untreated HIV-infected women and infected women on
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antiretroviral therapy. However, cesarean delivery is associated with greater morbidity
than vaginal delivery among both HIV-infected and noninfected women (58 ). In 1999 and
2000, the American College of Obstetricians and Gynecologists (ACOG) recommended
offering scheduled cesarean delivery at 38 weeks gestation to reduce the risk for vertical
transmission of HIV infection (57,59 ). Other intrapartum interventions alone (e.g.,
vaginal disinfection during labor and cleansing of the newborn) have not proven
effective (60 ).
Follow-Up Care for Infected Women and Perinatally Exposed Infants
Providing mothers and their infants with ongoing HIV-related care can maximize the
benefits of prevention interventions. The medical care of HIV-infected women is a com-
plicated task requiring use of potent combinations of antiretroviral drugs, monitoring of
viral load and drug resistance, treatment and prophylaxis of opportunistic infections, and
monitoring of immune status. In addition to conditions (e.g., Pneumocystis carinii pneu-
monia [PCP]) for which all immunocompromised HIV-infected persons are at risk, women
experience specific manifestations of HIV disease (e.g., aggressive pelvic inflammatory
disease and persistent and difficult-to-treat vaginal yeast infections requiring frequent
screening and treatment) (61,62 ). HIV-infected women are also at increased risk for
cervical dysplasia, which can result in cancer (63 ). With early detection and appropriate
treatment, many of these complications can be prevented and treated. Improved health
outcomes resulting from advances in HIV management and treatment depend not only
on access to medical care but also on access to prevention and psychosocial support
services. In the United States, most mothers and children with HIV/AIDS live in areas
where poverty, illicit drug use, poor housing, and limited access to and use of medical
care and social services add to the challenges of HIV disease (4,9 ). Women with HIV
infection often have difficulty gaining access to health care and frequently are respon-
sible for caring for children and other family members who might also be HIV-infected
(64 ). They often lack social support and face other challenges that could interfere with
their ability to gain access to and adhere to complicated treatment regimens. The com-
plex medical and social problems of families affected by HIV are best managed by
multidisciplinary case-management teams that integrate specialty medical care with
prevention, psychosocial, and other HIV-related services (see Revised Guidelines for HIV
Counseling, Testing, and Referral ).
Postnatal evaluation of infants at risk for HIV infection that begins immediately after
birth is the key to early diagnosis and optimal medical management of infected children.
PCP is the most common opportunistic infection in children with AIDS and is often fatal
(65 ). Because PCP occurs most often in perinatally infected children at ages 3–6 months
(65 ), effective prevention requires that children born to HIV-infected mothers be identi-
fied promptly, preferably through maternal testing, so that PCP prophylactic therapy can
be initiated at age 6 weeks. In 1995, CDC published revised guidelines recommending
PCP prophylaxis for all perinatally exposed infants at ages 4–6 weeks until their infection
status was determined (66 ). Perinatal screening can identify HIV-exposed infants early,
making it possible to follow infected children closely and promptly diagnose other poten-
tially treatable, HIV-related conditions (e.g., severe bacterial infections). This also allows
antiretroviral treatment to be initiated as soon as indicated to prevent morbidity, prolong
survival, and reduce the need for hospitalization (67 ).
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Follow-up of infants, both infected and uninfected, who are exposed to antiretroviral
drugs is critical to identifying potential short- and long-term toxicities. Data on the risks of
antiretroviral drugs during pregnancy are summarized and updated regularly (57 ).
Summary of IOM Recommendations
In 1996, Congress charged IOM with evaluating the extent to which state efforts had
been effective in reducing perinatal HIV transmission and analyzing barriers to further
reduction in such transmission. In 1999, IOM published its results, which addressed ways
to increase prenatal testing, improve therapy for HIV-infected women and children, and
generally reduce perinatal HIV infections (9 ).
Despite sharp reductions in perinatally transmitted AIDS cases that resulted from
widespread implementation of the 1994 and 1995 PHS guidelines, IOM reported that the
number of children born with HIV infection exceeded achievable prevention levels. Pre-
natal HIV testing was not universal, and many HIV-infected women were inadequately
treated because they did not seek prenatal care, were not tested for HIV, or received
treatment that did not reflect current standards. Even in settings where most prenatal-
care providers agreed that HIV tests should be offered to all pregnant women, some
reported that they did not offer the test to all women in their practices, mainly because
pretest counseling recommended by CDC and promulgated in some state policies were
too burdensome (9 ). Citing lack of time and skills for counseling, providers based testing
decisions on their own, often inaccurate, assessments of maternal risk.
IOM recommended that the United States adopt a goal that all pregnant women be
tested for HIV and all infected women receive optimal treatment for themselves and
their children. To help meet this goal, IOM recommended that the United States adopt a
policy of universal HIV testing, with patient notification, as a routine component of prena-
tal care (i.e., all pregnant women should be offered testing regardless of their risk factors
or the prevalence rates where they live). Early diagnosis of HIV infection allows pregnant
women to receive effective antiretroviral therapy for their own health and reduce the
risk for transmitting HIV to their infants. Universal testing avoids stereotyping or stigma-
tizing any socioeconomic or ethnic group. Women should be told they are being tested for
HIV and told of their right to refuse testing. Patient notification allows women to decline
testing if they feel it is not in their best interest and simplifies the testing process by
eliminating the need for extensive pretest counseling.
Legal Considerations
IOM’s recommendations prompted reconsideration of the focus, implementation, and
impact of PHS’s guidelines for HIV screening of pregnant women. These guidelines rec-
ommended counseling all pregnant women regarding the risk for HIV infection, benefits
of HIV testing, and voluntary testing. This approach was endorsed by most professional
organizations representing prenatal, obstetrical, and perinatal-care providers. States
quickly implemented the guidelines, but with substantial variability in strategy (68 ). Most
states responded with policies on HIV counseling and testing of pregnant women;
approximately 50% also enacted laws or regulations. Most policies and statutes are
directed at pregnant women rather than newborns and focus on education, counseling,
and consensual testing. New York and Connecticut are the only states that mandate
newborn testing. No evidence exists to indicate that any legal approach is more success-
ful than others in preventing perinatal transmission. No states require mandatory testing
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of pregnant women. In considering adopting the IOM guidelines, some states have imple-
mented or are considering requiring some form of pretest counseling, routine testing
with right of refusal, or universal or selective newborn screening. IOM’s recommenda-
tion is for universal HIV testing with patient notification. As states consider implementing
the IOM recommendations, other important considerations include availability of care
and treatment for HIV-infected mothers and their infants, provider training needs, and
confidentiality laws to protect positive test results reported to public health surveillance.
States should consult with public health officials, health-care providers, and representa-
tives of affected communities during this process.
For the individual woman, the substantial benefits of HIV testing must be weighed
against the possible risks. Potential negative consequences of a diagnosis of HIV infec-
tion can include loss of confidentiality, job- or health-care–related discrimination and
stigmatization, loss of relationships, domestic violence, and adverse psychological reac-
tions (69 ). Providing HIV-infected women with or referring them to psychological, social,
and legal services could help minimize these risks and allow more women to benefit from
the health advantages of early HIV diagnosis without adverse consequences. The Ameri-
cans with Disabilities Act (ADA) of 1990 and other federal, state, and local antidiscrimina-
tion provisions aim to protect persons with HIV/AIDS against discrimination in the
workplace, housing, public services, and public accommodations (70 ). A 1998 U.S.
Supreme Court decision provided further antidiscrimination protection by ensuring that
persons with asymptomatic HIV disease are included under ADA and have access to
nondiscriminatory and effective health care (70 ).
Laboratory Testing Considerations
Testing of women before or during pregnancy is typically conducted according to the
standard protocol for detection of antibody to HIV (71 ). For women with unknown HIV
status during active labor, antiretroviral treatment can still be effective when given dur-
ing labor and delivery, followed by treatment of the newborn (11 ). This expedited inter-
vention requires the use of rapid diagnostic testing during labor or rapid return of results
from standard testing.
Standard Testing Protocol
The HIV testing algorithm recommended by PHS consists of initial screening with an
FDA-licensed enzyme immunoassay (EIA) followed by confirmatory testing of repeat-
edly reactive EIAs with an FDA-licensed supplemental test (e.g., Western blot). Although
each test is highly sensitive and specific, using both increases the accuracy of results.
Indeterminate Western blot results can be caused by either incomplete antibody
response to HIV in samples from infected persons or nonspecific reactions in samples
from uninfected persons (72–74 ). Incomplete antibody responses that produce negative
or indeterminate results on Western blot tests can occur among persons recently
infected with HIV who have low levels of detectable antibodies (i.e., seroconversion),
persons who have end-stage HIV disease, and perinatally exposed but uninfected infants
who are seroreverting (i.e., losing maternal antibody). Nonspecific reactions producing
indeterminate results in uninfected persons have occurred more frequently among preg-
nant or parous women than among other persons (73,74 ). No large-scale studies have
been conducted to estimate the prevalence of indeterminate test results in pregnant
women. However, a survey of 1,044,944 neonatal dried-blood specimens tested by EIA
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for maternally acquired HIV-1 antibody indicated a relatively low rate of indeterminate
Western blot results (<1 in 4,000 specimens tested by EIA)  (74 ). Overall,  2,845 Western
blots were performed.
False-positive Western blot results (especially those with a majority of bands) are
rare. For example, in a study that used a sensitive culture technique to test approxi-
mately 290,000 blood donors , no false-positive Western blot results were detected (75 ).
In a study of the frequency of false-positive diagnoses among military applicants from a
low-prevalence population (i.e., <1.5 infections/1,000 population), one false-positive
result was detected among 135,187 persons tested (76 ).
An HIV test should be considered positive only after screening and confirmatory tests
are reactive. A confirmed positive test result indicates that a person has been infected
with HIV. False-positive results when both screening and confirmatory tests are reactive
are rare. However, the possibility of a mislabeled sample or laboratory error must be
considered, especially for a client with no identifiable risk for HIV infection. HIV vaccine-
induced antibodies may be detected by current tests and may cause a false-positive
result. Persons whose test results are HIV-positive and who are identified as vaccine trial
participants should be encouraged to contact or return to their trial site or an associated
trial site for HIV counseling, testing, and referral (CTR) services.
Incorrect HIV test results occur primarily because of specimen-handling errors, labo-
ratory errors, or failure to follow the recommended testing algorithm (76 ). However,
patients might report incorrect test results because they misunderstood previous test
results or misperceived that they were infected (77 ). Although these occurrences are
rare, increased testing of pregnant women will result in additional indeterminate, false-
positive, and incorrect results. Because of the significance of an HIV-positive test result,
its impact on a woman’s reproductive decisions, and the resulting need to consider HIV
therapeutic drugs for both a pregnant woman and her infant, previous guidelines have
emphasized that HIV test results must be obtained and interpreted correctly. In some
circumstances, correct interpretation might require consideration of not only additional
testing but also the woman’s clinical condition and history of possible exposure to HIV.
Diagnosis of HIV Infection in Newborns
The standard antibody assays used for older children and adults are less useful for
diagnosis of infection in children aged <18 months. Nearly all infants born to HIV-infected
mothers passively acquire maternal antibody and, in some cases, will test antibody
positive until age 18 months regardless of whether they are infected. Definitive diagno-
sis of HIV infection in early infancy requires other assays, including nucleic acid amplifi-
cation (e.g., polymerase chain reaction [PCR]) or viral culture. HIV infection is diagnosed
by two positive assays (PCR or viral culture) on two separate specimens. Infant HIV
testing should be done as soon after birth as possible so appropriate treatment interven-
tions can be implemented quickly (67 ).
Rapid Tests for Expedited Screening
For certain HIV-infected pregnant women, the labor and delivery setting is the first
opportunity for HIV testing and interruption of mother-to-child transmission. Although
results of conventional EIAs and Western blots are typically not available for 1–2 weeks,
rapid tests for detecting antibody to HIV can produce results in 10–60 minutes (78 ). The
sensitivity and specificity of rapid assays are comparable with EIAs. However, the pre-
dictive value of a single screening test varies with the prevalence of HIV infection among
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the population tested. Because HIV prevalence is low in most perinatal testing settings,
the negative predictive value of a single rapid test (i.e., the probability that a negative test
accurately indicates that the person tested is uninfected) is high. A negative rapid test
does not require further testing. In contrast, the positive predictive value of a single test
(i.e., the probability that a positive test represents true infection) will be low among
populations with low prevalence (71 ). Therefore, a reactive rapid test must be confirmed
by a supplemental test (e.g., Western blot). However, necessary peripartum interven-
tions to reduce the risk for perinatal transmission might need to be based on the prelimi-
nary results of rapid testing at labor and delivery. Decisions regarding use of antiretroviral
drugs to prevent perinatal transmission among women who are repeatedly reactive on
a single rapid HIV test require clinical judgment regarding initiation of prophylactic treat-
ment before results of a confirmatory test are available.
Only one FDA-approved rapid HIV test (Abbott Murex Single Use Diagnostic System
[SUDS] HIV-1 test, Abbott Laboratories, Inc., Abbott Park, Illinois) is commercially avail-
able in the United States, although other rapid tests are being considered for approval.
This test can provide definitive negative and preliminary positive test results at the time
of testing and identify women who might need antiretroviral treatment and whose in-
fants might benefit from chemoprophylaxis. A careful risk assessment could help make
treatment decisions. The predictive value of a reactive rapid test is higher among per-
sons with risk for HIV infection, especially in areas with high HIV prevalence (79 ). Use of
a second screening test (either rapid test or EIA) can also improve the positive predictive
value of a single reactive rapid HIV test. In studies conducted outside the United States,
specific combinations of >2 different screening assays provided results as reliable as
those from the conventional EIA/Western blot combination (80 ).
Expedited EIA testing that produces results within a few hours can also aid decisions
regarding antiretroviral therapy. Although results from standard testing are not likely to
be available during labor and delivery, they could be available within 12 hours of an
infant’s birth. Because neonatal prophylaxis might be effective in reducing risk for trans-
mission (24 ), expedited application of the standard testing protocol is another way to
reduce mother-to-child infection.
Research and programmatic studies are underway to assess the feasibility of offer-
ing voluntary HIV counseling and rapid testing at labor and delivery to women of
unknown serostatus in the United States. Implementation of rapid testing and expedited
EIA approaches should address several ethical and logistical considerations, including
• acceptability of rapid HIV testing in the labor room,
• difficulty in obtaining informed consent for testing and treatment during labor or
soon after birth,
• acceptance of intrapartum and postpartum ZDV prophylaxis for the mother or
infant,
• optimal timing of posttest counseling,
• logistical concerns for providers,
• implications of preliminary reactive test results, and
• comprehension of discussions regarding antiretroviral treatment by women who
are in labor (81,82 ).
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A CDC-funded, multicenter initiative called Mother-Infant Rapid Intervention at
Delivery (MIRIAD) is underway to address these considerations among women with
inadequate prenatal care in communities with high HIV seroprevalence among women
of childbearing age (81 ). If successful, this initiative will offer crucial peripartum inter-
ventions to reduce the risk for HIV transmission among HIV-infected women first identi-
fied at labor and delivery.
RECOMMENDATIONS
The following revised recommendations for HIV screening of pregnant women are
based on scientific and clinical advances in preventing perinatally acquired HIV and
caring for HIV-infected women, recommendations from IOM, consultations with special-
ists in the field, and public opinion. They reflect the need for universal HIV testing of all
pregnant women and simplification of the pretest process so that operational proce-
dures do not impede women from benefitting from proven measures to prevent perina-
tal transmission and from other advances in the care and treatment of HIV disease.
Although universal testing is recommended, testing should remain a voluntary decision
by the pregnant woman.
Screening for HIV in Pregnant Women and Their Infants
• PHS recommends that all pregnant women in the United States be tested for HIV
infection. All health-care providers should recommend HIV testing to all of their
pregnant patients, pointing out the substantial benefit of knowledge of HIV status
for the health of women and their infants. HIV screening should be a routine part of
prenatal care for all women.
• HIV testing should be voluntary and free of coercion. Informed consent before HIV
testing is essential. Information regarding consent can be presented orally or in
writing and should use language the client understands. Accepting or refusing
testing must not have detrimental consequences to the quality of prenatal care
offered. Documentation of informed consent should be in writing, preferably with
the client’s signature. State or local laws and regulations governing HIV testing
should be followed. HIV testing should be presented universally as part of routine
services to pregnant women, and confidential informed consent should be
maintained (see Revised Guidelines for HIV Counseling, Testing, and Referral ).
• Although HIV testing is recommended, women should be allowed to refuse testing.
Women should not be tested without their knowledge. Women who refuse testing
should not be coerced into testing, denied care for themselves or their infants, or
threatened with loss of custody of their infants or other negative consequences.
Discussing and addressing reasons for refusal (e.g., lack of awareness of risk or
fear of the disease, partner violence, potential stigma, or discrimination) could
promote health education and trust-building and allow some women to accept
testing at a later date. Women who refuse testing because of a previous history of
a negative HIV test should be informed of the importance of retesting during
pregnancy. All logistical reasons for not testing (e.g., scheduling) should be
addressed as well. Health-care providers should remember that some women
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who initially refuse testing might accept at a later date, particularly if their concerns
are discussed. Some women who refuse confidential testing might be willing to
obtain anonymous testing. However, they should be informed that if they choose
anonymous testing, no documentation of the results will be recorded in the medical
chart, and their providers might have to retest them, potentially delaying provision
of antiretoviral drugs for therapy or perinatal prophylaxis. Some women will
continue to refuse testing, and their decisions should be respected.
• Before HIV testing, health-care providers should provide the following minimum
information. Although a face-to-face counseling session is ideal, other methods can
be used (e.g., brochure, pamphlet, or video) if they are culturally and linguistically
appropriate.
— HIV is the virus that causes AIDS. HIV is spread through unprotected sexual
contact and injection-drug use. Approximately 25% of HIV-infected pregnant
women who are not treated during pregnancy can transmit HIV to their infants
during pregnancy, during labor and delivery, or through breast-feeding.
— A woman might be at risk for HIV infection and not know it, even if she has had
only one sex partner.
— Effective interventions (e.g., highly active combination antiretrovirals) for HIV-
infected pregnant women can protect their infants from acquiring HIV and can
prolong the survival and improve the health of these mothers and their children.
— For these reasons, HIV testing is recommended for all pregnant women.
— Services are available to help women reduce their risk for HIV and to provide
medical care and other assistance to those who are infected.
— Women who decline testing will not be denied care for themselves or their
infants.
• Health-care providers should perform HIV testing in consenting women as early as
possible during pregnancy to promote informed and timely therapeutic decisions.
Retesting in the third trimester, preferably before 36 weeks of gestation, is
recommended for women known to be at high risk for acquiring HIV (e.g., those
who have a history of sexually transmitted diseases [STDs], who exchange sex for
money or drugs, who have multiple sex partners during pregnancy, who use illicit
drugs, who have sex partner[s] known to be HIV-positive or at high risk, and who
have signs and symptoms of seroconversion). Routine universal retesting in the
third trimester may be considered in health-care facilities with high HIV
seroprevalence among women of childbearing age. Retesting for syphilis during
the third trimester and again at delivery also is recommended for pregnant women
at high risk (83 ). Some states mandate syphilis screening at delivery for all
pregnant women.
• Women admitted for labor and delivery with unknown or undocumented HIV status
should be assessed promptly for HIV infection to allow for timely prophylactic
treatment. Expedited testing by either rapid return of results from standard testing
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or use of rapid testing (with confirmation by a second licensed test when available)
is recommended for these women. The goal is to identify HIV-infected women or
their infants as soon as possible because the efficacy of prophylactic therapy is
greatest if given during or as soon after exposure as possible (i.e., within 12 hours
of birth). Informed consent is essential for women tested prenatally, and women in
labor with unknown status should be allowed to refuse testing without undue
consequences. After delivery, standard confirmatory testing should be done for
women with positive rapid test results.
• Some women might not a) receive testing during labor and delivery, b) choose to
be tested for HIV, or c) retain custody of their infants. If the mother has not been
tested for HIV, she should be informed that knowing her infant’s infection status has
benefits for the infant’s health and that HIV testing is recommended for her infant.
Providers should ensure that the mother understands that a positive HIV antibody
test for her infant indicates infection in herself. For infants whose HIV infection
status is unknown and who are in foster care, the person legally authorized to
provide consent should be informed that HIV testing is recommended for infants
whose biological mothers have not been tested. Testing should be performed in
accordance with the policies of the organization legally responsible for the child
and with prevailing legal requirements for HIV testing of children.
• Regulations, laws, and policies regarding HIV screening of pregnant women and
infants are not standardized throughout all states and U.S. territories. Health-care
providers should be familiar with and adhere to state/local laws, regulations, and
policies concerning HIV screening of pregnant women and infants.
Education and Prevention Counseling of Pregnant Women
Regarding HIV
When the pretest process is simplified to providing essential information, the value of
prevention counseling should not be lost. For some women, the prenatal care period
could be an ideal opportunity for HIV prevention and subsequent behavior change to
reduce risk for acquiring HIV infection. Thus, the following steps are recommended:
• Information regarding HIV and assessment of risks for HIV infection (i.e., risk
screening) should be provided to all pregnant women as part of routine health
education. Reluctance to provide HIV prevention counseling should never be a
barrier to HIV testing. Similarly, a focus on increased HIV testing should not be a
barrier to providing effective HIV prevention counseling for persons determined to
be at increased risk for acquiring or transmitting HIV (see Revised Guidelines for
HIV Counseling, Testing, and Referral ).
• Pregnant women found to have behaviors that place them at high risk for acquiring
HIV infection (e.g., multiple sex partners, current diagnosis or history of STDs,
exchange of sex for money or drugs, substance abuse) or who want more
intensive client-centered HIV prevention counseling should be provided with or
referred to HIV risk-reduction services (e.g., drug treatment, STD treatment, HIV
centers with personnel trained in HIV counseling).
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Interpretation of HIV Test Results
• HIV antibody testing should be performed according to the recommended
algorithm, which includes an EIA to test for antibody to HIV and confirmatory
testing with a more specific assay (e.g., Western blot). All assays should be
performed according to manufacturers’ instructions and state and federal
laboratory guidelines.
• HIV infection (as indicated by the presence of antibody to HIV) is defined as a
repeatedly reactive EIA and a positive confirmatory supplemental test.
Confirmation or exclusion of HIV infection in a person with indeterminate test
results should be based on HIV antibody test results, consideration of the person’s
medical and behavioral history, results from additional virologic and immunologic
tests when performed, and clinical follow-up (see Revised Guidelines for HIV
Counseling, Testing, and Referral ). Whenever possible, uncertainties regarding
HIV infection status, including laboratory test results, should be resolved before
final decisions are made regarding reproductive options, antiretroviral therapy,
cesarean delivery, or other interventions.
• Pregnant women who have repeatedly reactive EIAs and indeterminate
supplemental tests should be retested for HIV antibody to distinguish between
recent seroconversion and a negative test result. Almost all nonpregnant HIV-
infected persons with indeterminate Western Blot will develop detectable HIV
antibody within 1 month of exposure to the virus; relevant data are not available
for pregnant women. Although viral DNA/RNA assays can be helpful, they are not
FDA-approved for diagnostic use.
• Women who have negative EIA or rapid test results and those who have
repeatedly reactive EIAs but negative supplemental tests should be considered
uninfected unless they have had a recent HIV exposure. A negative test result
provides information regarding the woman’s status, but does not ensure that a
sexual or needle-sharing partner is uninfected.
• As additional rapid assays become licensed and available in the United States,
specific combinations of >2 different rapid HIV tests for diagnosis of HIV infection in
women who do not receive health care until labor might be useful because
combinations of rapid tests have provided results as reliable as those from the EIA/
Western blot combination (78 ). Until other rapid assays are available, some
women who are reactive on a single rapid test might consider prophylactic
treatment until HIV infection is ruled out. Confirmatory standard testing should be
done after delivery for women with a positive rapid test result.
Recommendations for HIV-Infected Pregnant Women
• HIV-infected pregnant women should receive HIV prevention counseling as
recommended (see Revised Guidelines for HIV Counseling, Testing, and Referral ).
This counseling should include discussion of the risk for perinatal HIV transmission,
ways to reduce this risk, and the prognosis for infants who become infected.
HIV-infected pregnant women should also be told the clinical implications of a
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positive HIV antibody test result and the need for and benefit of HIV-related
medical and other early intervention services, including how to access these
services.
• HIV-infected pregnant women should be counseled regarding antiretroviral
therapy during pregnancy to improve their health (84 ) and prevent perinatal
transmission (57 ). Medical care and management of HIV-infected persons,
especially pregnant women, can be complicated because of the need for
combination therapy with multiple drugs, management of common side effects,
careful monitoring of viral load and drug resistance, prophylaxis for and treatment
of opportunistic infections, and monitoring of immune status. Health-care
providers who are not experienced in the care of pregnant HIV-infected women
are encouraged to obtain referral for specialty care from providers who are
knowledgeable in this area.
Although pregnancy is not an adequate reason to defer therapy for HIV infection,
unique considerations exist regarding use of antiretroviral drugs during pregnancy,
including the potential need to alter dosing because of physiologic changes associated
with pregnancy, the potential for adverse short- or long-term effects on the fetus and
infant, and the effectiveness in reducing the risk for perinatal transmission (57 ).
• Obstetric providers should adhere to best obstetric practices, including offering
scheduled cesarean section at 38 weeks to reduce risk for perinatal HIV
transmission (60,85 ).
• HIV-infected pregnant women should receive information regarding all
reproductive options. Reproductive counseling should be nondirective. Health-
care providers should be aware of the complex concerns that HIV-infected women
must consider when making decisions regarding their reproductive options and
should be supportive of any decision.
• To eliminate the risk for postnatal transmission, HIV-infected women in the United
States should not breast-feed. Support services for use of appropriate breast milk
substitutes should be provided when necessary. UNAIDS and World Health
Organization recommendations for HIV and breast-feeding should be followed in
international settings (86 ).
• To optimize medical management, positive and negative HIV test results should be
available to a woman’s health-care provider and included on her confidential
medical records and those of her infant. After informing the mother, maternal
health-care providers should notify the pediatric-care providers of the impending
birth of an HIV-exposed infant and any anticipated complications. If HIV is first
diagnosed in the infant, health-care providers should discuss the implications for
the mother’s health and help her obtain care. Women should also be encouraged to
have their other children tested for HIV. Children can be infected with HIV for many
years before complications occur. Providers are encouraged to build supportive
health-care relationships that promote discussion of pertinent health information.
Confidential HIV-related information should be disclosed or shared only in
accordance with prevailing legal requirements.
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• After receiving their test results, HIV-infected pregnant women should receive
counseling, including assessment of the potential for negative effects (e.g.,
discrimination, domestic violence, psychological difficulties). Counseling should
also include information on how to minimize these consequences, assistance in
identifying supportive persons in their own social networks, and referral to
appropriate psychological, social, and legal services. HIV-infected women should
be counseled regarding the risk for transmission to others and ways to decrease
this risk. They also should be told that discrimination based on HIV status or AIDS in
housing, employment, state programs, and public accommodations (including
physicians’ offices and hospitals) is illegal.
• Health-care providers should thoroughly assess the prevention service needs of
HIV-infected women (e.g., substance abuse, STD treatment, partner referral, or
family planning services) and develop a plan to promote access to and use of these
services (see Revised Guidelines for HIV Counseling, Testing, and Referral ).
• Health-care providers should follow the Public Health Service Task Force
recommendations for using antiretroviral drugs to treat pregnant HIV-1 infected
women and reduce perinatal HIV-1 transmission in the United States, which
address treating pregnant women who do not receive health care until near the
time of delivery. These recommendations are available at the HIV/AIDS Treatment
Information Service (ATIS) website at <http://www.hivatis.org> (57 ).
Recommendations for Postpartum Follow-Up of Infected
Women and Perinatally Exposed Children
• HIV-infected women should receive ongoing HIV-related medical care, including
immune-function monitoring, recommended therapy, and prophylaxis for and
treatment of opportunistic infections and other HIV-related conditions (84,87 ). HIV-
infected women should receive gynecologic care, including regular Pap smears,
reproductive counseling, information on how to prevent sexual and drug-related
transmission of HIV, and treatment of gynecologic conditions according to
published recommendations (87 ). Obstetrical providers should ensure that HIV-
infected women are introduced or referred to another provider to continue their
care after pregnancy.
• HIV-infected women (or their children’s guardians) should be informed of the
importance of follow-up for their children. Children whose HIV infection status is
unknown require early diagnostic testing and prophylactic therapy to prevent PCP
pending determination of their status.
— Infected children require follow-up care to determine the need for prophylactic
therapy and antiretroviral treatment and to monitor disorders in growth and
development that often occur before age 24 months.
— Uninfected children who are exposed to antiretroviral therapy should be
assessed for potential short- and long-term side effects.
• Identification of an HIV-infected mother indicates that her family needs or will need
medical and social services as her disease progresses. Thus, health-care providers
should ensure that referrals to services address the needs of the entire family.
Vol. 50 / No. RR-19 MMWR 81
CONCLUSION
Because of recent advances in both antiretroviral and obstetrical interventions, preg-
nant women infected with HIV who know their status prenatally can reduce their risk for
transmitting HIV to their infants to <2%. The guidelines in this report are intended to
reduce barriers to voluntary HIV testing for all pregnant women in the United States and
to make the voluntary counseling and testing process simple and routine in prenatal
settings. The recommendations underscore the importance of HIV-infected pregnant
women (and their health-care providers) knowing their status to protect their own health
and reduce the risk for transmitting HIV to their infants.
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answer will instruct you to “Indicate all that apply.”
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(ACCME) to provide continuing medical education for physicians. CDC designates this educational activity for a maximum
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GOAL AND OBJECTIVES
This MMWR provides recommendations regarding the screening of pregnant women for human
immunodeficiency virus (HIV) infection. These recommendations were prepared by the U.S. Public Health
Service based on public health and obstetric practice guidelines and input from a panel of specialists. The goal
of this report is to provide guidance to public- and private-sector policy makers and clinical providers on HIV
screening during pregnancy. Upon completion of this continuing education activity, the reader should be able
to a) describe the recommended HIV counseling and testing strategy for pregnant women, b) identify risk factors
for perinatal HIV transmission, c) identify barriers to HIV testing among pregnant women, and d) describe the
information that pregnant women should receive before HIV testing.
To receive continuing education credit, please answer all of the following questions.
1. The recommended testing strategy for pregnant women can best be described as
A. universal counseling and voluntary HIV testing.
B. routine counseling and targeted testing.
C. voluntary counseling and testing.
D. targeted counseling and testing.
2. The new guidelines differ from the 1995 guidelines for HIV counseling and testing for
pregnant women in all of the following ways except
A. making the consent process more flexible.
B. strengthening the recommendation that all pregnant women be tested for HIV.
C. placing more emphasis on HIV testing and treatment at the time of delivery.
D. recommending simplification of the testing process.
E. none of the above.
3. All of the following factors have been associated with increased risk for perinatal HIV
transmission except
A. advanced maternal HIV disease.
B. prolonged rupture of membranes.
C. scheduled cesarean delivery.
D. preterm delivery.
E. maternal infection with another sexually transmitted disease (STD).
4. All of the following are reasons commonly cited by women for declining HIV testing except
A. no perceived risk.
B. financial constraints.
C. administrative scheduling difficulties.
D. lack of provider endorsement.
E. history of previous testing.
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5. Which of the following are included as one of the components of the recommended
Pediatric AIDS Clinical Trials Group protocol 076 regimen for administration of zidovudine
(ZDV)?
A. Administration of oral ZDV to the infant for the first 8 weeks of life.
B. Administration of oral ZDV to the mother beginning during the first trimester.
C. Administration of intravenous ZDV to the infant at time of birth.
D. Administration of intravenous ZDV during labor and delivery.
6. All of the following information should be provided to pregnant women before HIV testing
except
A. Effective interventions can help protect infants from becoming infected.
B. Services are available to help women reduce their risk for HIV.
C. A woman might be at risk for HIV and not know it.
D. Repeat HIV testing is not recommended for women tested within the year.
E. HIV can be transmitted through breast-feeding.
7. Retesting for HIV in the third trimester is recommended for
A. women with a history of STDs.
B. women with multiple sex partners during pregnancy.
C. A and B.
D. none of the above.
8. Informed consent before HIV testing is
A. optional.
B. mandated by federal law.
C. essential.
D. required by most states.
9. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organizations.
E. Academic institution.
F. Other.
10. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.
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11. I plan to use these recommendations as the basis for . . . (Indicate all that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.






13. How much time did you spend reading this report and completing the exam?
A. Fewer than 1.5 hours.
B. More than 1.5 hours but fewer than 2 hours.
C. 1–1.5 hours.
D. More than 2.5 hours but fewer than 3 hours.
E. 3 hours or more.
14. After reading this report, I am confident I can describe the recommended HIV counseling
and testing strategy for pregnant women.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can describe the information that pregnant
women should receive before HIV testing.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. The recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–8
1. A; 2. E; 3. C; 4. B; 5. D; 6. D; 7. C; 8. C.
21. How did you learn about this continuing education activity?
A. Internet.
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